SenesTech (SNES) 10-K 21 Feb 24 2023 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2023	Feb. 20, 2024	Jun. 30, 2023
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Current Fiscal Year End Date	--12-31
Document Period End Date	Dec. 31, 2023
Document Transition Report	false
Entity File Number	001-37941
Entity Registrant Name	SENESTECH, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-2079805
Entity Address, Address Line One	23460 N. 19th Ave
Entity Address, Address Line Two	Suite 110
Entity Address, City or Town	Phoenix
Entity Address, State or Province	AZ
Entity Address, Postal Zip Code	85027
City Area Code	(928)
Local Phone Number	779-4143
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	SNES
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction	false
Entity Shell Company	false
Entity Public Float			$ 3,320,000
Entity Common Stock, Shares Outstanding (in shares)		5,144,632
Documents Incorporated by Reference	Documents Incorporated by Reference Portions of the registrant’s definitive proxy statement for the 2024 Annual Meeting of Stockholders are incorporated by reference into Part III of this Form 10-K.
Entity Central Index Key	0001680378
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY
Amendment Flag	false

AUDIT INFORMATION

AUDIT INFORMATION	12 Months Ended
	Dec. 31, 2023
Audit Information [Abstract]
Auditor Firm ID	2738
Auditor Name	M&K CPAS, PLLC
Auditor Location	Houston, TX

BALANCE SHEETS

BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 5,395	$ 4,775
Accounts receivable, net	95	113
Prepaid expenses	388	378
Inventory, net	795	853
Total current assets	6,673	6,119
Right to use assets, operating leases	210	347
Property and equipment, net	388	294
Other noncurrent assets	22	22
Total assets	7,293	6,782
Current liabilities:
Accounts payable	150	540
Accrued expenses	368	560
Current portion of operating lease liability	217	180
Current portion of notes payable	33	0
Deferred revenue	18	44
Total current liabilities	786	1,324
Operating lease liability, less current portion	0	179
Notes payable, less current portion	156	0
Total liabilities	942	1,503
Commitments and contingencies (see notes)
Stockholders’ equity:
Preferred stock, $0.001 par value, 10,000,000 shares authorized, none issued and outstanding	0	0
Common stock, $0.001 par value, 100,000,000 shares authorized, 5,140,024 and 67,472 shares issued and outstanding as of December 31, 2023 and 2022, respectively	5	0
Additional paid-in capital	136,259	127,482
Accumulated deficit	(129,913)	(122,203)
Total stockholders’ equity	6,351	5,279
Total liabilities and stockholders’ equity	$ 7,293	$ 6,782

BALANCE SHEETS (Parenthetical)

BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	5,140,024	67,472
Common stock, shares outstanding (in shares)	5,140,024	67,472

STATEMENTS OF OPERATIONS AND CO

STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Total revenues	$ 1,193	$ 1,019
Cost of sales	654	555
Gross profit	539	464
Operating expenses:
Research and development	1,228	1,859
Selling, general and administrative	7,043	8,279
Total operating expenses	8,271	10,138
Loss from operations	(7,732)	(9,674)
Other income (expense):
Interest income	26	7
Interest expense	(4)	(2)
Miscellaneous expense	0	(26)
Other income (expense), net	22	(21)
Net loss	(7,710)	(9,695)
Comprehensive loss	$ (7,710)	$ (9,695)
Weighted average shares outstanding - basic (in shares)	669,861	65,473
Weighted average shares outstanding - diluted (in shares)	669,861	65,473
Loss per share - basic (in dollars per share)	$ (11.51)	$ (148.08)
Loss per share - diluted (in dollars per share)	$ (11.51)	$ (148.08)

STATEMENTS OF CHANGES IN STOCKH

STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit
Beginning Balance (in shares) at Dec. 31, 2021		50,864
Beginning Balance at Dec. 31, 2021	$ 10,035	$ 0	$ 122,543	$ (112,508)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	707		707
Net proceeds received for issuance of common stock and prefunding of warrants (in shares)		5,631
Net proceeds received for issuance of common stock and prefunding of warrants	4,228		4,228
Issuance of common stock upon exercise of warrants, net (in shares)		10,916
Issuance of common stock for services (in shares)		57
Issuance of common stock for services	$ 4		4
Issuance of common stock for fractional shares in the reverse stock split (in shares)	4
Net loss	$ (9,695)			(9,695)
Ending Balance (in shares) at Dec. 31, 2022	67,472	67,472
Ending Balance at Dec. 31, 2022	$ 5,279	$ 0	127,482	(122,203)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	455		455
Net proceeds received for issuance of common stock and prefunding of warrants (in shares)		521,735
Net proceeds received for issuance of common stock and prefunding of warrants	5,407		5,407
Issuance of common stock upon exercise of warrants, net (in shares)		4,544,437
Issuance of common stock upon exercise of warrants, net	2,831	$ 5	2,826
Issuance of common stock for services (in shares)		4,539
Issuance of common stock for services	100		100
Issuance of shares pursuant to the vesting of restricted stock units, net of shares withheld for taxes (in shares)		1,102
Issuance of shares pursuant to the vesting of restricted stock units, net of shares withheld for taxes	(11)		(11)
Issuance of common stock for fractional shares in the reverse stock split (in shares)		739
Net loss	$ (7,710)			(7,710)
Ending Balance (in shares) at Dec. 31, 2023	5,140,024	5,140,024
Ending Balance at Dec. 31, 2023	$ 6,351	$ 5	$ 136,259	$ (129,913)

STATEMENTS OF CHANGES IN STOC_2

STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (Parenthetical)		12 Months Ended
	Nov. 16, 2023	Dec. 31, 2023	Dec. 31, 2022
Statement of Stockholders' Equity [Abstract]
Stock split ratio, common stock	0.0833	0.0833	0.05

STATEMENTS OF CASH FLOWS

STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities:
Net loss	$ (7,710)	$ (9,695)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	135	183
Stock-based compensation	555	711
Loss on sale of equipment	0	28
Bad debt expense	(2)	6
Changes in operating assets and liabilities:
Accounts receivable	20	(42)
Other assets	(4)	0
Prepaid expenses	(10)	(148)
Inventory	58	148
Accounts payable	(390)	206
Accrued expenses	(192)	(18)
Deferred revenue	(26)	44
Net cash used in operating activities	(7,566)	(8,577)
Cash flows from investing activities:
Proceeds received on sale of property and equipment	0	4
Purchase of property and equipment	(149)	(174)
Net cash used in investing activities	(149)	(170)
Cash flows from financing activities:
Proceeds from the issuance of common stock, net	5,407	4,228
Proceeds from the exercise of warrants	2,831	0
Proceeds from the issuance of notes payable	114	0
Repayments of notes payable	(6)	(5)
Repayments of finance lease obligations	0	(27)
Payment of employee withholding taxes related to share based awards	(11)	0
Net cash provided by financing activities	8,335	4,196
Increase (decrease) in cash and cash equivalents	620	(4,551)
Cash and cash equivalents, beginning of year	4,775	9,326
Cash and cash equivalents, end of year	5,395	4,775
Cash paid for:
Interest paid	4	1
Income taxes paid	0	0
Non-cash investing and financing activities:
Notes payable incurred for the purchase of certain equipment	$ 81	$ 0

BASIS OF PRESENTATION

BASIS OF PRESENTATION	12 Months Ended
	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION Nature of Business SenesTech, Inc. (referred to in this report as “SenesTech,” the “Company,” “we” or “us”) was incorporated in the state of Nevada in July 2004. On November 15, 2015, the Company subsequently reincorporated in the state of Delaware. Our corporate headquarters and manufacturing site are in Phoenix, Arizona. We have developed and are commercializing a global, proprietary technology for managing animal pest populations, initially rat populations, through fertility control with our current products known as ContraPest and Evolve. ContraPest is a liquid bait containing the active ingredients 4-vinylcyclohexene diepoxide and triptolide. ContraPest limits reproduction of male and female rats beginning with the first breeding cycle following consumption. ContraPest is being marketed for use in controlling Norway and roof rat populations. In addition to the EPA registration of ContraPest in the United States, we must obtain registration from the various state regulatory agencies prior to selling in each state. To date, we have received registration for ContraPest in all 50 states and the District of Columbia, 49 of which have approved the removal of the Restricted Use designation, as well as the District of Columbia and five major U.S. territories. In November 2023, we launched our latest product, Evolve, a soft bait containing the active ingredient cottonseed oil. Evolve limits reproduction of male and female rats after one to two breeding cycles following consumption. Evolve is being marketed for use in controlling rat populations as a minimum risk pesticide under the U.S. Environmental Protection Agency Federal Insecticide, Fungicide, and Rodenticide Act, Section 25(b). We must obtain registration from the various state regulatory agencies that do not accept the federal exemption. To date, we are authorized to sell Evolve in 30 states. Reverse Stock Split On November 16, 2023, we amended our amended and restated certificate of incorporation to effect a 1-for-12 reverse split of our issued and outstanding shares of common stock. The accompanying financial statements and notes thereto give retrospective effect to the reverse stock split for all periods presented. All issued and outstanding common stock, options and warrants exercisable for common stock, restricted stock units and per share amounts contained in our financial statements have been retrospectively adjusted. Going Concern Although our audited financial statements for the years ended December 31, 2023 and December 31, 2022 were prepared under the assumption that we would continue our operations as a going concern, the report of our independent registered public accounting firm that accompanies our financial statements for the years ended December 31, 2023 and December 31, 2022 contains a going concern qualification in which such firm expressed substantial doubt in our ability to continue as a going concern without additional capital from becoming available, based on the financial statements at that time. Specifically, as noted above, we have incurred operating losses since our inception, and we expect to continue to incur significant expenses and operating losses for the foreseeable future. These prior losses and expected future losses have had, and will continue to have, an adverse effect on our financial condition. If we encounter continued issues or delays in the commercialization of ContraPest, our prior losses and expected future losses could have an adverse effect on our financial condition and negatively impact our ability to fund continued operations, obtain additional financing in the future and continue as a going concern. There are no assurances that such financing, if necessary, will be available to us at all or will be available in sufficient amounts or on reasonable terms. Our financial statements do not include any adjustments that may result from the outcome of this uncertainty. If we are unable to generate additional funds in the future through financings, sales of our products, licensing fees, royalty payments or from other sources or transactions, we will exhaust our resources and will be unable to continue operations. Need for Additional Capital Since our inception, we have sustained significant operating losses in the course of our research and development and commercialization activities and expect such losses to continue for the near future. We have generated limited revenue to date from product sales, research grants and licensing fees from a former license. We have primarily funded our operations to date through the sale of equity securities, including convertible preferred stock, common stock and warrants to purchase common stock; and debt financing, consisting primarily of convertible notes. As of December 31, 2023, we had an accumulated deficit of $129.9 million and cash and cash equivalents of $5.4 million. Our ultimate success depends upon the outcome of a combination of factors, including the following: (i) successful commercialization of ContraPest and Evolve and maintaining and obtaining regulatory approval of our products and product candidates; (ii) market acceptance, commercial viability and profitability of ContraPest, Evolve and other products; (iii) the ability to market our products and establish an effective sales force and marketing infrastructure to generate significant revenue; (iv) the success of our research and development; (v) the ability to retain and attract key personnel to develop, operate and grow our business; and (vi) our ability to meet our working capital needs. Based upon our current operating plan, we expect that cash and cash equivalents at December 31, 2023, in combination with anticipated revenue, will be sufficient to fund our current operations for at least the next nine months. We have evaluated and will continue to evaluate our operating expenses and will concentrate our resources toward the successful commercialization of ContraPest and Evolve in the United States and globally. However, if anticipated revenue targets and margin targets are not achieved or expenses are more than we have budgeted, we may need to raise additional financing before that time. If we need more financing, including within the next nine months, and we are unable to raise necessary capital through the sale of our securities, we may be required to take other measures that could impair our ability to be successful and operate as a going concern. In any event, we may require additional capital in order to fund our operating losses and research and development activities before we become profitable and may opportunistically raise capital. We may never achieve profitability or generate positive cash flows, and unless and until we do, we will continue to need to raise capital through equity or debt financing. If such equity or debt financing is not available at adequate levels or on acceptable terms, we may need to delay, limit or terminate commercialization and development efforts or discontinue operations. Use of Estimates The preparation of our financial statements and related disclosures in accordance with U.S. GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue, costs and expenses, and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different conditions.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Cash and Cash Equivalents Highly liquid investments with maturities of three months or less as the date of acquisition are classified as cash equivalents, of which we had $4.2 million and $4.4 million as of December 31, 2023 and 2022, respectively, included within Cash and cash equivalents in the balance sheets. Accounts Receivable Accounts receivable are recorded at invoiced amounts based on standard prices and do not bear interest. We provide an allowance for doubtful receivables equal to the estimated uncollectible amounts. That estimate is based on historical collection experience, current economic and market conditions and a review of the current status of each customer’s trade accounts receivable. Provisions for uncollectible accounts receivable are charged to Selling, general and administrative expense, with an offsetting credit to the allowance for uncollectible accounts. Inventories Inventories consist of raw materials, work in progress and finished goods and are stated at the lower of cost or market value, using the first-in, first-out convention. Cost includes the acquired cost of raw materials, with work-in-progress and finished goods including the application of labor and overhead costs related to the manufacturing process. Raw materials are stocked to reduce the risk of impact on manufacturing for any potential supply interruptions or long lead times on certain ingredients. Reserves for obsolete inventory consist of reserves primarily related to obsolete product containers and delivery systems. Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Equipment held under finance leases are stated at the present value of minimum lease payments less accumulated amortization. Depreciation on property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets as follows: Research and development equipment 5 years Office and computer equipment 3 years Autos 5 years Furniture and fixtures 7 years The cost of leasehold improvements is amortized over the life of the improvement or the term of the lease, whichever is shorter. Equipment held under finance leases are amortized over the shorter of the lease term or estimated useful life of the asset. The Company incurs maintenance costs on its major equipment. Repair and maintenance costs are expensed as incurred. Impairment of Long-Lived Assets Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require long-lived assets or asset groups to be tested for possible impairment, the Company compares the undiscounted cash flows expected to be generated from the use of the asset or asset group to its carrying amount. If the carrying amount of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment charge is recognized to the extent that the carrying amount exceeds its fair value. Fair value is determined through various valuation techniques, such as discounted cash flow models and the use of third- party independent appraisals. We have not recorded an impairment of long-lived assets since our inception. Revenue Recognition In accordance with Accounting Standards Codification (“ASC”) 606 — Revenue from Contracts with Customers (“ASC 606”), we recognize revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. We derive revenue primarily from commercial sales of products, net of discounts and promotions, as well as consulting and implementation services provided in conjunction with our product deployments. We recognize revenue when product is shipped at a fixed selling price with payment terms of 30 to 120 days from invoicing. We recognize any other revenue earned from pilot studies, consulting and implementation services upon the performance of specific services under the respective service contract. Research and Development Research and development costs are expensed as incurred. Research and development expenses primarily consist of salaries and benefits for research and development employees, stock-based compensation, consulting fees, lab supplies, costs incurred related to conducting scientific trials and field studies, regulatory compliance costs, as well as manufacturing costs associated with process improvement and other research. Research and development expenses include an allocation of facilities related costs, including depreciation of equipment. Stock-based Compensation Stock-based awards, consisting of stock options and restricted stock units expected to be settled in shares of our common stock, are recorded as equity awards. The grant date fair value of these awards is measured using the Black-Scholes option pricing model for stock options and grant date market value for restricted stock units. We expense the grant date fair value of our stock-based awards on a straight-line basis over their respective vesting periods. Advertising Costs Advertising costs are expensed as incurred and was $238,000 and $369,000 for the years ended December 31, 2023 and 2022, respectively. Income Taxes We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax bases of assets and liabilities and net operating loss carryforwards using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the period that includes the enactment date. We record net deferred tax assets to the extent we believe these assets will more likely than not be realized. These deferred tax assets are subject to periodic assessments as to recoverability and if it is determined that it is more likely than not that the benefits will not be realized, valuation allowances are recorded which would increase the provision for income taxes. In making such determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations. We currently maintain a full valuation allowance against its deferred tax assets. We apply a more-likely-than-not recognition threshold for all tax uncertainties. Only those benefits that have a greater than fifty percent likelihood of being sustained upon examination by the taxing authorities are recognized. Based on our evaluation, we have concluded there are no significant uncertain tax positions requiring recognition in our financial statements. We recognize interest and/or penalties related to uncertain tax positions in income tax expense. There are no uncertain tax positions as of December 31, 2023 or December 31, 2022 and as such, no interest or penalties were recorded in income tax expense. Comprehensive Loss We have no other comprehensive income items for the periods presented. As a result, our net loss and comprehensive loss were the same for all periods presented and a separate statement of comprehensive loss is not included in the accompanying financial statements.

BALANCE SHEET COMPONENTS

BALANCE SHEET COMPONENTS	12 Months Ended
	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BALANCE SHEET COMPONENTS	BALANCE SHEET COMPONENTS Accounts Receivable, Net Accounts receivable, net consist of the following (in thousands): As of December 31, 2023 2022 Accounts receivable $ 99 $ 119 Allowance for uncollectible accounts (4) (6) Accounts receivable, net $ 95 $ 113 The following is the activity in the allowance for uncollectible accounts (in thousands): Years Ended December 31, 2023 2022 Balance as of beginning of year $ 6 $ — Increase in provision 2 8 Amounts written off, less recoveries (4) (2) Balance as of end of year $ 4 $ 6 Inventory, Net Inventory, net consist of the following (in thousands): As of December 31, 2023 2022 Raw materials $ 747 $ 772 Finished goods 53 99 Total inventory 800 871 Reserve for obsolescence (5) (18) Inventory, net $ 795 $ 853 The following is the activity in the reserve for obsolescence (in thousands): Years Ended December 31, 2023 2022 Balance as of beginning of year $ 18 $ 29 Increase in reserve — — Amounts relieved (13) (11) Balance as of end of year $ 5 $ 18 Prepaid Expenses Prepaid expenses consist of the following (in thousands): As of December 31, 2023 2022 Software licenses $ 152 $ 157 Prepaid inventory 111 — Insurance 64 61 Professional services 30 41 Patents 14 39 Marketing programs and conferences 1 74 Other 16 6 Total prepaid expenses $ 388 $ 378 Property and Equipment, Net Property and equipment, net consist of the following (in thousands): As of December 31, 2023 2022 Research and development equipment $ 1,763 $ 1,558 Office and computer equipment 808 800 Autos 54 54 Furniture and fixtures 41 41 Leasehold improvements 141 119 Total in service 2,807 2,572 Accumulated depreciation and amortization (2,419) (2,283) Total in service, net 388 289 Construction in progress — 5 Property and equipment, net $ 388 $ 294 During the years ended December 31, 2023 and 2022, depreciation and amortization expense was $135,000 and $183,000, respectively. Accrued Expenses Accrued expenses consist of the following (in thousands): As of December 31, 2023 2022 Compensation, severance and related benefits $ 232 $ 497 Legal services 121 36 Product warranty 15 18 Personal property and franchise tax — 6 Other — 3 Total accrued expenses $ 368 $ 560 Notes Payable In the second half of 2023, we arranged financing for the purchase of certain equipment. The notes payable have an annual interest rate of 9.1% with a term of five years and is secured by the underlying equipment. As of December 31, 2023, future principal payments were as follows (in thousands): 2024 $ 33 2025 36 2026 39 2027 43 2028 38 Total principal payments 189 Less: current portion of notes payable (33) Notes payable, less current portion $ 156

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	12 Months Ended
	Dec. 31, 2023
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	FAIR VALUE MEASUREMENTS The accounting guidance for fair value, among other things, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The framework for measuring fair value consists of a three-level valuation hierarchy that prioritizes the inputs to valuation techniques used to measure fair value based upon whether such inputs are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions made by the reporting entity. The three-level hierarchy for the inputs to valuation techniques is briefly summarized as follows: Level 1 — Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date; Level 2 — Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and Level 3 — Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data. An asset’s or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs. Assets and liabilities measured at fair value are based on one or more of the following three valuation techniques: A. Market approach: Prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities. B. Cost approach: Amount that would be required to replace the service capacity of an asset (replacement cost). C. Income approach: Techniques to convert future amounts to a single present amount based upon market expectations, including present value techniques, option-pricing and excess earnings models. Financial Instruments Not Carried at Fair Value The carrying amounts of our financial instruments, including accounts payable and accrued liabilities, approximate fair value due to their short maturities. The estimated fair value of the long-term debt, not recorded at fair value, are recorded at cost or amortized cost, which was deemed to estimate fair value.

LEASES

LEASES	12 Months Ended
	Dec. 31, 2023
Leases [Abstract]
LEASES	LEASES We determine if an arrangement is a lease at inception and whether the arrangement is classified as an operating or finance lease. At commencement of the lease, we record a right-of-use (“ROU”) asset and lease liability in the balance sheet based on the present value of lease payments over the term of the arrangement. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. If the implicit rate is not readily determinable in the contract, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Contract terms may include options to extend or terminate the lease, and, when we deem it is reasonably certain that we will exercise that option, it is included in the ROU asset and liability. Operating leases reflect lease expense on a straight-line basis, while any finance leases result in the separate presentation of interest expense on the lease liability and amortization expense of the ROU asset. We have operating leases for our corporate headquarters and our manufacturing and research facility, which expire in 2024. We were obligated under finance leases for certain research and computer equipment, of which the last arrangement expired in July 2022. The components of lease cost are as follows (in thousands): Years Ended December 31, 2023 2022 Operating lease cost $ 231 $ 222 Finance lease cost: Amortization of ROU asset — 35 Interest on lease liability — 1 Total finance lease cost $ — $ 36 As of December 31, 2023, maturities of operating lease liabilities are follows (in thousands): Years Ending December 31: 2024 $ 225 Total operating lease payments 225 Less imputed interest (8) Total operating lease liabilities $ 217
LEASES	LEASES We determine if an arrangement is a lease at inception and whether the arrangement is classified as an operating or finance lease. At commencement of the lease, we record a right-of-use (“ROU”) asset and lease liability in the balance sheet based on the present value of lease payments over the term of the arrangement. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. If the implicit rate is not readily determinable in the contract, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Contract terms may include options to extend or terminate the lease, and, when we deem it is reasonably certain that we will exercise that option, it is included in the ROU asset and liability. Operating leases reflect lease expense on a straight-line basis, while any finance leases result in the separate presentation of interest expense on the lease liability and amortization expense of the ROU asset. We have operating leases for our corporate headquarters and our manufacturing and research facility, which expire in 2024. We were obligated under finance leases for certain research and computer equipment, of which the last arrangement expired in July 2022. The components of lease cost are as follows (in thousands): Years Ended December 31, 2023 2022 Operating lease cost $ 231 $ 222 Finance lease cost: Amortization of ROU asset — 35 Interest on lease liability — 1 Total finance lease cost $ — $ 36 As of December 31, 2023, maturities of operating lease liabilities are follows (in thousands): Years Ending December 31: 2024 $ 225 Total operating lease payments 225 Less imputed interest (8) Total operating lease liabilities $ 217

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	12 Months Ended
	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION In 2018, our stockholders approved the adoption of the SenesTech, Inc. 2018 Equity Incentive Plan (the “2018 Plan”). The 2018 Plan has since been amended and restated on certain occasions, most recently on June 23, 2023, when our stockholders approved an increase to the total number of authorized shares to 70,717 shares. Stock options are generally issued with a per share exercise price equal to the fair market value of our common stock at the date of grant. Options granted generally vest immediately, or ratably over a two As of December 31, 2023, we had 42,008 shares of common stock available for issuance under the 2018 Plan. Stock Options We measure the fair value of stock options with service-based vesting criteria to employees, directors and consultants on the date of grant using the Black-Scholes option pricing model. The Black-Scholes valuation model requires us to make certain estimates and assumptions, including assumptions related to the expected price volatility of our stock, the period during which the options will be outstanding, the rate of return on risk-free investments, and the expected dividend yield for our stock. Fair value of options granted is determined using the Black-Scholes option-pricing model with the following weighted average assumptions: 2023 2022 Risk-free interest rate 5.3 % 3.7 % Expected dividend yield — % — % Expected volatility 128 % 90.5 % Expected term (in years) 5.0 3.3 The weighted average fair value of options granted during the years ended December 31, 2023 and 2022 was $14.88 and $41.04 per share, respectively. The risk-free interest rate is estimated using treasury bill interest rates. The expected dividend yield is no as we have not paid any dividends to date and do not expect to pay dividends in the future. Expected volatility is estimated based on the historical volatility of our common stock over the expected term as this represents our best estimate of future volatility. The contractual life of stock options granted is five years, and we have elected to use the “simplified method” to estimate expected term. Under the simplified method, an option’s expected term is calculated as the average of its vesting period and original contractual life. For non-employee options, the expected term of options granted is the contractual term of the options. The stock option activity consists of the following: Number of Weighted Weighted Aggregate Intrinsic Value (1) Outstanding as of December 31, 2021 4,533 $ 2,071.20 3.9 $ — Granted 20,163 69.48 5.0 — Exercised — — — — Forfeited (1,278) — — — Expired (16) — — — Outstanding as of December 31, 2022 23,402 204.00 3.9 — Granted 16,616 15.00 5.0 — Exercised — — — — Forfeited (3,282) — — — Expired (28) — — — Outstanding as of December 31, 2023 36,708 119.70 4.0 — Exercisable as of December 31, 2023 20,634 (2) 154.31 3.8 — (1) Calculated based on the difference between the estimated fair value of our stock and the exercise price of the underlying option. The estimated stock values used in the calculation was $15.00 and $71.52 per share for the years ended December 31, 2023 and 2022, respectively. (2) Includes options related to 8,249 shares that are inducement awards and not granted under the 2018 Plan. As of December 31, 2023, the unrecognized stock-based compensation cost was $293,000, which is expected to be recognized over a weighted average period of 13 months. Restricted Stock Units The restricted stock unit activity consists of the following: Number of Weighted Average Outstanding as of December 31, 2021 2 $ 432.00 Granted 1,587 34.44 Vested (23) 212.04 Forfeited — — Outstanding as of December 31, 2022 1,566 32.52 Granted — — Vested (1,566) 32.52 Forfeited — — Outstanding as of December 31, 2023 — — The stock-based compensation expense was recorded as following (in thousands): Years Ended December 31, 2023 2022 Research and development $ 17 $ 3 General and administrative 538 (1) 708 Total stock-based compensation expense $ 555 $ 711 (1) Includes $100,000 related to stock issued in exchange for marketing services.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES Our losses before income taxes for the years ended December 31, 2023 and December 31, 2022 were generated entirely from U.S. operations. We have no current or deferred provision for income taxes from continuing operations for the years ended December 31, 2023 and 2022. The significant differences between the U.S. Federal statutory rate and our effective rate for financial reporting purposes are as follows: Years Ended December 31, 2023 2022 Federal statutory tax rate (21.0) % (21.0) % State taxed, net of federal tax benefit (3.8) (3.7) Change in valuation allowance 23.5 14.3 Return-to-provision and other 0.1 7.9 Stock-based compensation 1.2 2.5 Effective tax rate — % — % Deferred income tax assets and liabilities consist of the following (in thousands): As of December 31, 2023 2022 Deferred income tax assets: Federal and state net operating loss carryovers $ 22,167 $ 20,498 Capitalized research costs 608 432 Stock-based compensation 260 253 Compensation accruals and other 59 92 Operating leases related to ROU assets 54 89 Deferred revenue 4 11 Depreciation 11 8 Other 2 1 Total deferred income tax assets 23,165 21,384 Valuation allowance for deferred income tax assets (23,113) (21,298) Deferred income tax assets, net of valuation allowance 52 86 Deferred income tax liabilities: ROU assets (52) (86) Total deferred income tax liabilities (52) (86) Deferred income tax assets, net $ — $ — A valuation allowance has been recognized to offset the net deferred tax assets as realization of such deferred tax assets have not met the more likely than not threshold. As of December 31, 2023, we had federal and state net operating loss carryforwards of approximately $91.2 million and $78.0 million, respectively, not considering the IRC Section 382 annual limitation discussed below. The federal loss carryforwards begin to expire in 2029, unless previously utilized. In addition, we have approximately $46.8 million of the total $91.2 million of net operating losses that do not expire, as these losses were generated after the law change introduced as part of the Tax Cuts and Jobs Act. The state net operating losses expire if not utilized by 2043. Additionally, the utilization of the net operating loss carryforwards could be subject to an annual limitation under Section 382 and 383 of the Internal Revenue Code of 1986, and similar state tax provisions due to ownership change limitations that have occurred previously or that could occur in the future. These ownership changes limit the amount of net operating loss carryforwards and other deferred tax assets that can be utilized to offset future taxable income and tax, respectively. In general, an ownership change, as defined by Section 382 and 383, results from transactions increasing ownership of certain stockholders or public groups in the stock of the corporation by more than 50 percentage points over a three-year period. We have not conducted an analysis of an ownership change under Section 382. To the extent that a study is completed and an ownership change is deemed to occur, our net operating losses could be limited. We do not have any unrecognized tax benefits at the beginning and end of the years ended December 31, 2023 and 2022, and do not expect a significant change in unrecognized tax benefits over the next 12 months. We file income tax returns in the United States and Arizona with general statutes of limitations of three and four years, respectively. Due to net operating losses incurred, our tax returns from inception to date are subject to examination by taxing authorities. Our policy is to recognize interest expense and penalties related to income tax matters as a component of income tax expense. As of December 31, 2023, we had no interest or penalties accrued related to uncertain tax positions.

STOCKHOLDERS_ EQUITY

STOCKHOLDERS’ EQUITY	12 Months Ended
	Dec. 31, 2023
Stockholders' Equity Note [Abstract]
STOCKHOLDERS’ EQUITY	STOCKHOLDERS’ EQUITY Preferred Stock We are authorized to issue 10 million shares of preferred stock with a par value of $0.001. Rights and any series designation would be established at time of issuance of preferred stock. As of December 31, 2023 and 2022 there was no preferred stock outstanding. Common Stock We are authorized to issue 100 million shares of common stock with a par value of $0.001 per share. Stockholders of common stock have unlimited voting rights and are entitled to receive the net assets of the Company upon dissolution, subject to the rights of the preferred stockholders, if any. We had the following common stock offerings in 2023 and 2022: November 2022 . We consummated a private placement with certain institutional and accredited investors and issued an aggregate of 5,631 shares of our common stock at a purchase price of $42.00 per share, pre-funded warrants to purchase up to an aggregate of 113,416 shares of common stock at a purchase price of $42.00 per pre-funded warrant (“November 2022 Pre-Funded Warrants”) and associated warrants to purchase up to an aggregate of 238,094 share of common stock at $37.98 per share (“Series A” and “Series B” warrants), for gross proceeds of approximately $5.0 million, prior to deducting placement agent fees and offering expenses of $770,000. In connection with this offering, we issued the placement agent warrants to purchase up to 8,931 shares of common stock with an exercise price of $52.50 per share. Of the November 2022 Pre-Funded Warrants,10,916 were exercised in December 2022, with the remaining 102,500 exercised in early 2023. The common stock, November 2022 Pre-Funded Warrants and Series A and Series B warrants issued in this November 2022 offering were offered and sold pursuant to a registration statement on Form S-1 (File No. 333-267991) initially filed with the SEC on October 24, 2022, as amended, which was declared effective by the SEC on November 16, 2022. April 2023 . We consummated a registered direct offering with certain institutional investors and issued an aggregate of 71,429 shares of our common stock at a purchase price of $21.00 per share and warrants to purchase up to an aggregate of 71,430 shares of common stock at a purchase price of $19.44 per share (“Series C” warrants), for gross proceeds of approximately $1.5 million, prior to deducting placement agent fees and offering expenses of $290,000. In connection with this offering, we issued the placement agent warrants to purchase up to 5,359 share of common stock with an exercise price of $26.25 per share. The common stock and Series C warrants issued in this April 2023 offering were offered and sold pursuant to a shelf registration statement on Form S-3 (File No. 333-261227) initially filed with the SEC on November 19, 2021, as amended, which was declared effective by the SEC on May 6, 2022, and a prospectus supplement dated April 10, 2023. November 2023 . We consummated a private placement with certain institutional and accredited investors and issued an aggregate of 450,306 shares of our common stock at a purchase price of $1.30 per share, pre-funded warrants to purchase up to an aggregate of 3,395,848 shares of common stock at a purchase price of $1.30 per pre-funded warrant (“November 2023 Pre-Funded Warrants”) and associated warrants to purchase up to an aggregate of 7,692,308 shares of common stock at $1.30 per share (“Series D” and “Series E” warrants), for gross proceeds of approximately $5.0 million, prior to deducting placement agent fees and offering expenses of $800,000. In connection with this offering, we issued the placement agent warrants to purchase up to 288,462 shares of common stock with an exercise price of $1.630 per share. All of the November 2023 Pre-Funded Warrants were exercised by December 31, 2023. The common stock, November 2023 Pre-Funded Warrants and Series D and Series E warrants issued in this November 2023 offering were offered and sold pursuant to a registration statement on Form S-1 (File No. 333-273370) initially filed with the SEC on July 21, 2023, as amended, which was declared effective by the SEC on November 27, 2023. The following is the activity for common stock warrants: Issue Date Warrant Type Term Exercise Balance Issued Exercised Expired Balance Issued Exercised Expired Balance November 2017 Common Stock Offering November 2022 $ 327.84 507 — — (507) — — — — — June 2018 Reissue December 2023 8,736.00 236 — — — 236 — — (236) — August 2018 Rights Offering July 2023 5,520.00 843 — — — 843 — — (843) — August 2018 Dealer Manager August 2023 8,280.00 55 — — — 55 — — (55) — July 2019 Dealer Manager July 2024 8,100.00 37 — — — 37 — — — 37 January 2020 Registered Direct Offering July 2025 2,160.00 765 — — — 765 — — — 765 January 2020 Dealer Manager July 2025 2,400.00 57 — — — 57 — — — 57 March 2020 Dealer Manager March 2025 901.51 57 — — — 57 — — — 57 April 2020 Dealer Manager April 2025 952.80 493 — — — 493 — — — 493 April 2020 Registered Direct Offering April 2025 732.00 209 — — — 209 — — — 209 October 2020 Private Inducement November 2027 37.98 4,166 — — — 4,166 — (4,166) — — October 2020 Dealer Manager April 2026 517.44 356 — — — 356 — — — 356 February 2021 Private Placement Agreement August 2026 531.84 6,867 — — — 6,867 — — (1,372) 5,495 February 2021 Private Placement Agreement November 2027 37.98 2,285 — — — 2,285 — (2,285) — — February 2021 Dealer Manager August 2026 683.54 1,374 — — — 1,374 — — — 1,374 March 2021 Dealer Manager March 2026 600.00 619 — — — 619 — — — 619 November 2022 Pre-Funded Warrants February 2023 42.00 — 113,416 (10,916) — 102,500 — (102,500) — — November 2022 Series A November 2027 37.98 — 119,047 — — 119,047 — (119,047) — — November 2022 Series B December 2023 37.98 — 119,047 — — 119,047 — (119,047) — — November 2022 Dealer Manager November 2027 52.50 — 8,931 — — 8,931 — — — 8,931 April 2023 Series C October 2028 19.44 — — — — — 71,430 — — 71,430 April 2023 Dealer Manager April 2028 26.25 — — — — — 5,359 — — 5,359 August 2023 Private Inducement September 2024 8.64 — — — — — 238,096 — — 238,096 August 2023 Private Inducement August 2028 8.64 — — — — — 251,001 — — 251,001 August 2023 Dealer Manager August 2028 10.80 — — — — — 12,229 — — 12,229 November 2023 Pre-Funded Warrants December 2023 1.30 — — — — — 3,395,848 (3,395,848) — — November 2023 Series D November 2028 1.30 — — — — — 3,846,154 (30,000) — 3,816,154 November 2023 Series E May 2025 1.30 — — — — — 3,846,154 (771,544) — 3,074,610 November 2023 Dealer Manager November 2028 1.63 — — — — — 288,462 — — 288,462 18,926 360,441 (10,916) (507) 367,944 11,954,733 (4,544,437) (2,506) 7,775,734 As of December 31, 2023, we had 7,775,734 shares of common stock issuable upon exercise of outstanding common stock warrants, at a weighted-average exercise price of $2.95 per share and expiring as follows: Weighted Average Exercise Price Shares Years Ending December 31: 2024 $ 9.90 238,133 2025 2.10 3,076,191 2026 563.14 7,844 2027 52.50 8,931 2028 2.08 4,444,635 2.95 7,775,734 Common Stock Warrants Issued in November 2022 Common Stock Offering In November 2022, in connection with a registered direct offering with certain institutional and accredited investors, we issued common stock warrants as follows: • Pre-Funded Warrants to purchase up to an aggregate of 113,416 shares of common stock at an exercise price of $42.00 per share, which are exercisable immediately and terminate until exercised in full. A portion of the Pre-Funded Warrants were exercised in December 2022, with the last traunch of these warrants being exercised in February 2023. We estimated the fair value of the Pre-Funded Warrants to be $153,000 using a Black Scholes model based on the following significant inputs: common stock price of $36.36 per share; comparable company volatility of 93.9%; remaining term of three months; dividend yield of 0% and risk-free interest rate of 3.8%. • Series A warrants to purchase up to an aggregate of 119,047 shares at an exercise price of $37.980 per share, which are exercisable immediately and expire five years from date of issuance. We estimated the fair value of the Series A warrants to be $3.1 million using a Black Scholes model based on the following significant inputs: common stock price of $36.36 per share; comparable company volatility of 93.9%; remaining term of five years; dividend yield of 0% and risk-free interest rate of 3.8%. • Series B warrants to purchase up to an aggregate of 119,047 shares at an exercise price of $37.98 per share, which are exercisable immediately and expire 13 months from date of issuance. We estimated the fair value of the Series B warrants to be $1.6 million using a Black Scholes model based on the following significant inputs: common stock price of $36.36 per share; comparable company volatility of 93.9%; remaining term of five years; dividend yield of 0% and risk-free interest rate of 3.8%. In August 2023, certain terms of the Series A and Series B warrants were modified to induce exercise. The exercise price was reduced to $8.64 per share, and the warrants were exercised in full (“Warrant Inducement Transaction”). The offsetting impact related to the warrant inducement transaction was $657,000 , which was calculated as the difference between the fair value of the warrants immediately prior to modification and immediately after modification using the Black-Scholes model based on the following significant inputs: common stock price of $8.18 per share; volatility of 96%; term of 2.3 years; dividend yield of 0%; and risk-free rate of 5.0%. Common Stock Warrants Issued to Placement Agent in November 2022 Common Stock Offering In connection with the registered direct offering in November 2022, we issued to the placement agent, warrants to purchase up to 8,931 shares of common stock. The placement agent warrants will be exercisable commencing six months following the date of issuance, expire five years following the date of sale and have an exercise price per share of $52.50 per share. The placement agent warrants, and the shares of common stock issuable upon exercise thereof, will be issued in reliance on the exemption from registration provided in Section 4(a)(2) under the Securities Act of 1933, as amended, and Regulation D promulgated thereunder. We estimated the fair value of these warrants to be $240,000 using a Black Scholes model based on the following significant inputs: common stock price of $39.00; comparable company volatility of 93.9%; remaining term five years; dividend yield of 0%; and risk-free interest rate of 3.8%. Common Stock Warrants Issued in April 2023 Registered Direct Offering In April 2023, Series C warrants were issued to the investors to purchase up to 71,430 shares of our common stock. The Series C warrants are exercisable immediately with an exercise price of $19.44 per share and expire October 12, 2028. We estimated the fair value of these warrants to be $1.1 million using a Black-Scholes model based on the following significant inputs: common stock price of $16.56 per share; volatility of 164%; term of 5.5 years; dividend yield of 0%; and risk-free interest rate of 3.4%. In April 2023, placement agent warrants were issued to purchase up to 5,359 shares of our common stock. The placement agent warrants are exercisable immediately upon issuance, with an exercise price per share of $26.25 per share, and expire April 10, 2028. We estimated the fair value of these warrants to be $82,000 using a Black-Scholes model based on the following significant inputs: common stock price of $16.56 per share; volatility of 165%; term of 5 years; dividend yield of 0%; and risk-free interest rate of 3.5%. Common Stock Warrants Issued in August 2023 Private Inducement In August 2023, in connection with the Warrant Inducement Transaction, warrants were issued to the investor in the Warrant Inducement Transaction to purchase up to 489,097 shares of our common stock. These warrants are exercisable immediately with an exercise price of $8.64 per share, with 251,001 expiring August 2028 (“5-Year Warrants”) and 238,096 expiring September 2024 (“13-Month Warrants”). We estimated the fair value of the 5-Year Warrants to be $1.5 million using a Black-Scholes model based on the following significant inputs: common stock price of $8.18 per share; volatility of 98%; term of 5 years; dividend yield of 0%; and risk-free rate of 4.4%. The fair value of the 13-Month Warrants was estimated to be $930,000 using the Black-Scholes model based on the following significant inputs: common stock price of $8.18 per share; volatility of 122%; term of 1.1 years; dividend yield of 0%; and risk-free rate of 4.4%. In August 2023, placement agent warrants were issued to purchase up to 12,229 shares of our common stock. The placement agent warrants are exercisable immediately upon issuance, with an exercise price per share of $10.80 per share, and expire August 2028. We estimated the fair value of these warrants to be $72,000 using a Black-Scholes model based on the following significant inputs: common stock price of $8.18 per share; volatility of 98%; term of 5 years; dividend yield of 0%; and risk-free interest rate of 5.4%. Common Stock Warrants Issued in November 2023 Common Stock Offering In November 2023, in connection with a registered direct offering with certain institutional and accredited investors, we issued common stock warrants as follows: • Pre-Funded Warrants to purchase up to an aggregate of 3,395,848 shares of common stock at an exercise price of $1.30 per share, which are exercisable immediately and terminate only when exercised in full. These warrants were exercised in full by December 31, 2023. We estimated the fair value of the Pre-Funded Warrants to be $685,000 using a Black Scholes model based on the following significant inputs: common stock price of $0.93 per share; volatility of 262%; remaining term of one month; dividend yield of 0% and risk-free interest rate of 5.5%. • Series D warrants to purchase up to an aggregate of 3,846,154 shares at an exercise price of $1.30 per share, which are exercisable immediately and expire November 2028.We estimated the fair value of the Series D warrants to be $2.6 million using a Black Scholes model based on the following significant inputs: common stock price of $0.93 per share; volatility of 103%; remaining term of 5 years; dividend yield of 0% and risk-free interest rate of 4.2%. • Series E warrants to purchase up to an aggregate of 3,846,154 shares at an exercise price of $1.30 per share, which are exercisable immediately and expire May 2025. We estimated the fair value of the Series E warrants to be $1.8 million using a Black Scholes model based on the following significant inputs: common stock price of $0.93 per share; volatility of 128%; remaining term of 1.5 years; dividend yield of 0% and risk-free interest rate of 4.6%. Common Stock Warrants Issued to Placement Agent in November 2023 Common Stock Offering In connection with the registered direct offering in November 2023, we issued to the placement agent, warrants to purchase up to 288,462 shares of common stock. The placement agent warrants will be exercisable commencing six months following the date of issuance, expire five years following the date of sale and have an exercise price per share of $1.63 per share. The placement agent warrants, and the shares of common stock issuable upon exercise thereof, will be issued in reliance on the exemption from registration provided in Section 4(a)(2) under the Securities Act of 1933, as amended, and Regulation D promulgated thereunder. We estimated the fair value of these warrants to be $189,000 using a Black Scholes model based on the following significant inputs: common stock price of $0.93 per share; volatility of 103%; remaining term of five years; dividend yield of 0%; and risk-free interest rate of 4.2%.

COMMON STOCK WARRANTS

COMMON STOCK WARRANTS	12 Months Ended
	Dec. 31, 2023
Equity [Abstract]
COMMON STOCK WARRANTS	STOCKHOLDERS’ EQUITY Preferred Stock We are authorized to issue 10 million shares of preferred stock with a par value of $0.001. Rights and any series designation would be established at time of issuance of preferred stock. As of December 31, 2023 and 2022 there was no preferred stock outstanding. Common Stock We are authorized to issue 100 million shares of common stock with a par value of $0.001 per share. Stockholders of common stock have unlimited voting rights and are entitled to receive the net assets of the Company upon dissolution, subject to the rights of the preferred stockholders, if any. We had the following common stock offerings in 2023 and 2022: November 2022 . We consummated a private placement with certain institutional and accredited investors and issued an aggregate of 5,631 shares of our common stock at a purchase price of $42.00 per share, pre-funded warrants to purchase up to an aggregate of 113,416 shares of common stock at a purchase price of $42.00 per pre-funded warrant (“November 2022 Pre-Funded Warrants”) and associated warrants to purchase up to an aggregate of 238,094 share of common stock at $37.98 per share (“Series A” and “Series B” warrants), for gross proceeds of approximately $5.0 million, prior to deducting placement agent fees and offering expenses of $770,000. In connection with this offering, we issued the placement agent warrants to purchase up to 8,931 shares of common stock with an exercise price of $52.50 per share. Of the November 2022 Pre-Funded Warrants,10,916 were exercised in December 2022, with the remaining 102,500 exercised in early 2023. The common stock, November 2022 Pre-Funded Warrants and Series A and Series B warrants issued in this November 2022 offering were offered and sold pursuant to a registration statement on Form S-1 (File No. 333-267991) initially filed with the SEC on October 24, 2022, as amended, which was declared effective by the SEC on November 16, 2022. April 2023 . We consummated a registered direct offering with certain institutional investors and issued an aggregate of 71,429 shares of our common stock at a purchase price of $21.00 per share and warrants to purchase up to an aggregate of 71,430 shares of common stock at a purchase price of $19.44 per share (“Series C” warrants), for gross proceeds of approximately $1.5 million, prior to deducting placement agent fees and offering expenses of $290,000. In connection with this offering, we issued the placement agent warrants to purchase up to 5,359 share of common stock with an exercise price of $26.25 per share. The common stock and Series C warrants issued in this April 2023 offering were offered and sold pursuant to a shelf registration statement on Form S-3 (File No. 333-261227) initially filed with the SEC on November 19, 2021, as amended, which was declared effective by the SEC on May 6, 2022, and a prospectus supplement dated April 10, 2023. November 2023 . We consummated a private placement with certain institutional and accredited investors and issued an aggregate of 450,306 shares of our common stock at a purchase price of $1.30 per share, pre-funded warrants to purchase up to an aggregate of 3,395,848 shares of common stock at a purchase price of $1.30 per pre-funded warrant (“November 2023 Pre-Funded Warrants”) and associated warrants to purchase up to an aggregate of 7,692,308 shares of common stock at $1.30 per share (“Series D” and “Series E” warrants), for gross proceeds of approximately $5.0 million, prior to deducting placement agent fees and offering expenses of $800,000. In connection with this offering, we issued the placement agent warrants to purchase up to 288,462 shares of common stock with an exercise price of $1.630 per share. All of the November 2023 Pre-Funded Warrants were exercised by December 31, 2023. The common stock, November 2023 Pre-Funded Warrants and Series D and Series E warrants issued in this November 2023 offering were offered and sold pursuant to a registration statement on Form S-1 (File No. 333-273370) initially filed with the SEC on July 21, 2023, as amended, which was declared effective by the SEC on November 27, 2023. The following is the activity for common stock warrants: Issue Date Warrant Type Term Exercise Balance Issued Exercised Expired Balance Issued Exercised Expired Balance November 2017 Common Stock Offering November 2022 $ 327.84 507 — — (507) — — — — — June 2018 Reissue December 2023 8,736.00 236 — — — 236 — — (236) — August 2018 Rights Offering July 2023 5,520.00 843 — — — 843 — — (843) — August 2018 Dealer Manager August 2023 8,280.00 55 — — — 55 — — (55) — July 2019 Dealer Manager July 2024 8,100.00 37 — — — 37 — — — 37 January 2020 Registered Direct Offering July 2025 2,160.00 765 — — — 765 — — — 765 January 2020 Dealer Manager July 2025 2,400.00 57 — — — 57 — — — 57 March 2020 Dealer Manager March 2025 901.51 57 — — — 57 — — — 57 April 2020 Dealer Manager April 2025 952.80 493 — — — 493 — — — 493 April 2020 Registered Direct Offering April 2025 732.00 209 — — — 209 — — — 209 October 2020 Private Inducement November 2027 37.98 4,166 — — — 4,166 — (4,166) — — October 2020 Dealer Manager April 2026 517.44 356 — — — 356 — — — 356 February 2021 Private Placement Agreement August 2026 531.84 6,867 — — — 6,867 — — (1,372) 5,495 February 2021 Private Placement Agreement November 2027 37.98 2,285 — — — 2,285 — (2,285) — — February 2021 Dealer Manager August 2026 683.54 1,374 — — — 1,374 — — — 1,374 March 2021 Dealer Manager March 2026 600.00 619 — — — 619 — — — 619 November 2022 Pre-Funded Warrants February 2023 42.00 — 113,416 (10,916) — 102,500 — (102,500) — — November 2022 Series A November 2027 37.98 — 119,047 — — 119,047 — (119,047) — — November 2022 Series B December 2023 37.98 — 119,047 — — 119,047 — (119,047) — — November 2022 Dealer Manager November 2027 52.50 — 8,931 — — 8,931 — — — 8,931 April 2023 Series C October 2028 19.44 — — — — — 71,430 — — 71,430 April 2023 Dealer Manager April 2028 26.25 — — — — — 5,359 — — 5,359 August 2023 Private Inducement September 2024 8.64 — — — — — 238,096 — — 238,096 August 2023 Private Inducement August 2028 8.64 — — — — — 251,001 — — 251,001 August 2023 Dealer Manager August 2028 10.80 — — — — — 12,229 — — 12,229 November 2023 Pre-Funded Warrants December 2023 1.30 — — — — — 3,395,848 (3,395,848) — — November 2023 Series D November 2028 1.30 — — — — — 3,846,154 (30,000) — 3,816,154 November 2023 Series E May 2025 1.30 — — — — — 3,846,154 (771,544) — 3,074,610 November 2023 Dealer Manager November 2028 1.63 — — — — — 288,462 — — 288,462 18,926 360,441 (10,916) (507) 367,944 11,954,733 (4,544,437) (2,506) 7,775,734 As of December 31, 2023, we had 7,775,734 shares of common stock issuable upon exercise of outstanding common stock warrants, at a weighted-average exercise price of $2.95 per share and expiring as follows: Weighted Average Exercise Price Shares Years Ending December 31: 2024 $ 9.90 238,133 2025 2.10 3,076,191 2026 563.14 7,844 2027 52.50 8,931 2028 2.08 4,444,635 2.95 7,775,734 Common Stock Warrants Issued in November 2022 Common Stock Offering In November 2022, in connection with a registered direct offering with certain institutional and accredited investors, we issued common stock warrants as follows: • Pre-Funded Warrants to purchase up to an aggregate of 113,416 shares of common stock at an exercise price of $42.00 per share, which are exercisable immediately and terminate until exercised in full. A portion of the Pre-Funded Warrants were exercised in December 2022, with the last traunch of these warrants being exercised in February 2023. We estimated the fair value of the Pre-Funded Warrants to be $153,000 using a Black Scholes model based on the following significant inputs: common stock price of $36.36 per share; comparable company volatility of 93.9%; remaining term of three months; dividend yield of 0% and risk-free interest rate of 3.8%. • Series A warrants to purchase up to an aggregate of 119,047 shares at an exercise price of $37.980 per share, which are exercisable immediately and expire five years from date of issuance. We estimated the fair value of the Series A warrants to be $3.1 million using a Black Scholes model based on the following significant inputs: common stock price of $36.36 per share; comparable company volatility of 93.9%; remaining term of five years; dividend yield of 0% and risk-free interest rate of 3.8%. • Series B warrants to purchase up to an aggregate of 119,047 shares at an exercise price of $37.98 per share, which are exercisable immediately and expire 13 months from date of issuance. We estimated the fair value of the Series B warrants to be $1.6 million using a Black Scholes model based on the following significant inputs: common stock price of $36.36 per share; comparable company volatility of 93.9%; remaining term of five years; dividend yield of 0% and risk-free interest rate of 3.8%. In August 2023, certain terms of the Series A and Series B warrants were modified to induce exercise. The exercise price was reduced to $8.64 per share, and the warrants were exercised in full (“Warrant Inducement Transaction”). The offsetting impact related to the warrant inducement transaction was $657,000 , which was calculated as the difference between the fair value of the warrants immediately prior to modification and immediately after modification using the Black-Scholes model based on the following significant inputs: common stock price of $8.18 per share; volatility of 96%; term of 2.3 years; dividend yield of 0%; and risk-free rate of 5.0%. Common Stock Warrants Issued to Placement Agent in November 2022 Common Stock Offering In connection with the registered direct offering in November 2022, we issued to the placement agent, warrants to purchase up to 8,931 shares of common stock. The placement agent warrants will be exercisable commencing six months following the date of issuance, expire five years following the date of sale and have an exercise price per share of $52.50 per share. The placement agent warrants, and the shares of common stock issuable upon exercise thereof, will be issued in reliance on the exemption from registration provided in Section 4(a)(2) under the Securities Act of 1933, as amended, and Regulation D promulgated thereunder. We estimated the fair value of these warrants to be $240,000 using a Black Scholes model based on the following significant inputs: common stock price of $39.00; comparable company volatility of 93.9%; remaining term five years; dividend yield of 0%; and risk-free interest rate of 3.8%. Common Stock Warrants Issued in April 2023 Registered Direct Offering In April 2023, Series C warrants were issued to the investors to purchase up to 71,430 shares of our common stock. The Series C warrants are exercisable immediately with an exercise price of $19.44 per share and expire October 12, 2028. We estimated the fair value of these warrants to be $1.1 million using a Black-Scholes model based on the following significant inputs: common stock price of $16.56 per share; volatility of 164%; term of 5.5 years; dividend yield of 0%; and risk-free interest rate of 3.4%. In April 2023, placement agent warrants were issued to purchase up to 5,359 shares of our common stock. The placement agent warrants are exercisable immediately upon issuance, with an exercise price per share of $26.25 per share, and expire April 10, 2028. We estimated the fair value of these warrants to be $82,000 using a Black-Scholes model based on the following significant inputs: common stock price of $16.56 per share; volatility of 165%; term of 5 years; dividend yield of 0%; and risk-free interest rate of 3.5%. Common Stock Warrants Issued in August 2023 Private Inducement In August 2023, in connection with the Warrant Inducement Transaction, warrants were issued to the investor in the Warrant Inducement Transaction to purchase up to 489,097 shares of our common stock. These warrants are exercisable immediately with an exercise price of $8.64 per share, with 251,001 expiring August 2028 (“5-Year Warrants”) and 238,096 expiring September 2024 (“13-Month Warrants”). We estimated the fair value of the 5-Year Warrants to be $1.5 million using a Black-Scholes model based on the following significant inputs: common stock price of $8.18 per share; volatility of 98%; term of 5 years; dividend yield of 0%; and risk-free rate of 4.4%. The fair value of the 13-Month Warrants was estimated to be $930,000 using the Black-Scholes model based on the following significant inputs: common stock price of $8.18 per share; volatility of 122%; term of 1.1 years; dividend yield of 0%; and risk-free rate of 4.4%. In August 2023, placement agent warrants were issued to purchase up to 12,229 shares of our common stock. The placement agent warrants are exercisable immediately upon issuance, with an exercise price per share of $10.80 per share, and expire August 2028. We estimated the fair value of these warrants to be $72,000 using a Black-Scholes model based on the following significant inputs: common stock price of $8.18 per share; volatility of 98%; term of 5 years; dividend yield of 0%; and risk-free interest rate of 5.4%. Common Stock Warrants Issued in November 2023 Common Stock Offering In November 2023, in connection with a registered direct offering with certain institutional and accredited investors, we issued common stock warrants as follows: • Pre-Funded Warrants to purchase up to an aggregate of 3,395,848 shares of common stock at an exercise price of $1.30 per share, which are exercisable immediately and terminate only when exercised in full. These warrants were exercised in full by December 31, 2023. We estimated the fair value of the Pre-Funded Warrants to be $685,000 using a Black Scholes model based on the following significant inputs: common stock price of $0.93 per share; volatility of 262%; remaining term of one month; dividend yield of 0% and risk-free interest rate of 5.5%. • Series D warrants to purchase up to an aggregate of 3,846,154 shares at an exercise price of $1.30 per share, which are exercisable immediately and expire November 2028.We estimated the fair value of the Series D warrants to be $2.6 million using a Black Scholes model based on the following significant inputs: common stock price of $0.93 per share; volatility of 103%; remaining term of 5 years; dividend yield of 0% and risk-free interest rate of 4.2%. • Series E warrants to purchase up to an aggregate of 3,846,154 shares at an exercise price of $1.30 per share, which are exercisable immediately and expire May 2025. We estimated the fair value of the Series E warrants to be $1.8 million using a Black Scholes model based on the following significant inputs: common stock price of $0.93 per share; volatility of 128%; remaining term of 1.5 years; dividend yield of 0% and risk-free interest rate of 4.6%. Common Stock Warrants Issued to Placement Agent in November 2023 Common Stock Offering In connection with the registered direct offering in November 2023, we issued to the placement agent, warrants to purchase up to 288,462 shares of common stock. The placement agent warrants will be exercisable commencing six months following the date of issuance, expire five years following the date of sale and have an exercise price per share of $1.63 per share. The placement agent warrants, and the shares of common stock issuable upon exercise thereof, will be issued in reliance on the exemption from registration provided in Section 4(a)(2) under the Securities Act of 1933, as amended, and Regulation D promulgated thereunder. We estimated the fair value of these warrants to be $189,000 using a Black Scholes model based on the following significant inputs: common stock price of $0.93 per share; volatility of 103%; remaining term of five years; dividend yield of 0%; and risk-free interest rate of 4.2%.

LOSS PER SHARE

LOSS PER SHARE	12 Months Ended
	Dec. 31, 2023
Earnings Per Share [Abstract]
LOSS PER SHARE	LOSS PER SHARE Basic loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period, which includes prefunded warrants and any shares held in abeyance from date of issuance. Diluted loss per share is computed by dividing the loss attributable to common stockholders by the weighted average number of common shares used in the basic loss per share calculation plus potentially dilutive securities outstanding during the period determined using the treasury stock method. Stock options, warrants and restricted stock units are considered to be potentially dilutive securities but have been excluded from the calculation of diluted loss per share attributable to common stockholders because their effect would be anti-dilutive given the net loss reported for the years ended December 31, 2023 and 2022. Therefore, basic and diluted loss per share was the same for all periods presented. The following shares were excluded from the calculation of diluted loss per share: December 31, 2023 2022 Common stock warrants 6,755,010 172,473 Restricted stock units — 1,567 Common stock options — 10,052 Total 6,755,010 184,092

CONTINGENCIES

CONTINGENCIES	12 Months Ended
	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
CONTINGENCIES	CONTINGENCIES In July 2020, our former corporate general counsel (the “Plaintiff”), commenced an action against us in the Superior Court of the State of California, for the County of San Diego. The complaint alleged, among other things, that we breached the Plaintiff’s employment contract with us, as well as the implied covenant of good faith and fair dealing, by refusing to issue him the balance of stock options he claimed that we owed him. In September 2021, the Plaintiff served us and also named 10 individuals as defendants, consisting of current and former directors and employees. The Plaintiff alleged that such individuals agreed to knowingly and wrongfully withhold the stock options owed to him and were knowingly in receipt of stolen property. In November 2023, this legal matter was settled for $185,000.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2023
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	RELATED PARTY TRANSACTIONS Related party transactions are conducted in the normal course of business and, unless otherwise noted, are measured at the exchange amount, which is the amount of consideration established and agreed to by the related parties. In connection with consulting agreements in place, during each of the years ended December 31, 2023 and 2022, $4,200 and $50,400, respectively, of cash payments were made to the Kito Impact Foundation of which the Chair of our board, serves as chief executive officer.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTS Subsequent to December 31, 2023, 4,608 shares of common stock were issued pursuant to the exercise of certain warrants for gross proceeds of $6,000. We have evaluated subsequent events from the balance sheet date through February 21, 2024, the date at which the financial statements were issued, and determined that there were no other items that require adjustment to or disclosure in the financial statements.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Pay vs Performance Disclosure
Net loss	$ (7,710)	$ (9,695)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Dec. 31, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of our financial statements and related disclosures in accordance with U.S. GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue, costs and expenses, and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different conditions.
Cash and Cash Equivalents	Cash and Cash Equivalents Highly liquid investments with maturities of three months or less as the date of acquisition are classified as cash equivalents, of which we had $4.2 million and $4.4 million as of December 31, 2023 and 2022, respectively, included within Cash and cash equivalents in the balance sheets.
Accounts Receivable	Accounts Receivable Accounts receivable are recorded at invoiced amounts based on standard prices and do not bear interest. We provide an allowance for doubtful receivables equal to the estimated uncollectible amounts. That estimate is based on historical collection experience, current economic and market conditions and a review of the current status of each customer’s trade accounts receivable. Provisions for uncollectible accounts receivable are charged to Selling, general and administrative expense, with an offsetting credit to the allowance for uncollectible accounts.
Inventories	Inventories Inventories consist of raw materials, work in progress and finished goods and are stated at the lower of cost or market value, using the first-in, first-out convention. Cost includes the acquired cost of raw materials, with work-in-progress and finished goods including the application of labor and overhead costs related to the manufacturing process. Raw materials are stocked to reduce the risk of impact on manufacturing for any potential supply interruptions or long lead times on certain ingredients. Reserves for obsolete inventory consist of reserves primarily related to obsolete product containers and delivery systems.
Property and Equipment	Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Equipment held under finance leases are stated at the present value of minimum lease payments less accumulated amortization. Depreciation on property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets as follows: Research and development equipment 5 years Office and computer equipment 3 years Autos 5 years Furniture and fixtures 7 years The cost of leasehold improvements is amortized over the life of the improvement or the term of the lease, whichever is shorter. Equipment held under finance leases are amortized over the shorter of the lease term or estimated useful life of the asset. The Company incurs maintenance costs on its major equipment. Repair and maintenance costs are expensed as incurred.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require long-lived assets or asset groups to be tested for possible impairment, the Company compares the undiscounted cash flows expected to be generated from the use of the asset or asset group to its carrying amount. If the carrying amount of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment charge is recognized to the extent that the carrying amount exceeds its fair value. Fair value is determined through various valuation techniques, such as discounted cash flow models and the use of third- party independent appraisals. We have not recorded an impairment of long-lived assets since our inception.
Revenue Recognition	Revenue Recognition In accordance with Accounting Standards Codification (“ASC”) 606 — Revenue from Contracts with Customers (“ASC 606”), we recognize revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied.
Research and Development	Research and Development Research and development costs are expensed as incurred. Research and development expenses primarily consist of salaries and benefits for research and development employees, stock-based compensation, consulting fees, lab supplies, costs incurred related to conducting scientific trials and field studies, regulatory compliance costs, as well as manufacturing costs associated with process improvement and other research. Research and development expenses include an allocation of facilities related costs, including depreciation of equipment.
Stock-based Compensation	Stock-based Compensation Stock-based awards, consisting of stock options and restricted stock units expected to be settled in shares of our common stock, are recorded as equity awards. The grant date fair value of these awards is measured using the Black-Scholes option pricing model for stock options and grant date market value for restricted stock units. We expense the grant date fair value of our stock-based awards on a straight-line basis over their respective vesting periods.
Advertising Costs	Advertising Costs Advertising costs are expensed as incurred and was $238,000 and $369,000 for the years ended December 31, 2023 and 2022, respectively.
Income Taxes	Income Taxes We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax bases of assets and liabilities and net operating loss carryforwards using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the period that includes the enactment date. We record net deferred tax assets to the extent we believe these assets will more likely than not be realized. These deferred tax assets are subject to periodic assessments as to recoverability and if it is determined that it is more likely than not that the benefits will not be realized, valuation allowances are recorded which would increase the provision for income taxes. In making such determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations. We currently maintain a full valuation allowance against its deferred tax assets. We apply a more-likely-than-not recognition threshold for all tax uncertainties. Only those benefits that have a greater than fifty percent likelihood of being sustained upon examination by the taxing authorities are recognized. Based on our evaluation, we have concluded there are no significant uncertain tax positions requiring recognition in our financial statements.
Comprehensive Loss	Comprehensive Loss We have no other comprehensive income items for the periods presented. As a result, our net loss and comprehensive loss were the same for all periods presented and a separate statement of comprehensive loss is not included in the accompanying financial statements.
Fair Value Measurements	The accounting guidance for fair value, among other things, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The framework for measuring fair value consists of a three-level valuation hierarchy that prioritizes the inputs to valuation techniques used to measure fair value based upon whether such inputs are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions made by the reporting entity. The three-level hierarchy for the inputs to valuation techniques is briefly summarized as follows: Level 1 — Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date; Level 2 — Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and Level 3 — Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data. An asset’s or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs. Assets and liabilities measured at fair value are based on one or more of the following three valuation techniques: A. Market approach: Prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities. B. Cost approach: Amount that would be required to replace the service capacity of an asset (replacement cost). C. Income approach: Techniques to convert future amounts to a single present amount based upon market expectations, including present value techniques, option-pricing and excess earnings models.
Financial Instruments Not Carried at Fair Value	Financial Instruments Not Carried at Fair Value The carrying amounts of our financial instruments, including accounts payable and accrued liabilities, approximate fair value due to their short maturities. The estimated fair value of the long-term debt, not recorded at fair value, are recorded at cost or amortized cost, which was deemed to estimate fair value.
Leases	We determine if an arrangement is a lease at inception and whether the arrangement is classified as an operating or finance lease. At commencement of the lease, we record a right-of-use (“ROU”) asset and lease liability in the balance sheet based on the present value of lease payments over the term of the arrangement. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. If the implicit rate is not readily determinable in the contract, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Contract terms may include options to extend or terminate the lease, and, when we deem it is reasonably certain that we will exercise that option, it is included in the ROU asset and liability. Operating leases reflect lease expense on a straight-line basis, while any finance leases result in the separate presentation of interest expense on the lease liability and amortization expense of the ROU asset.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Schedule of property and equipment useful lives	Depreciation on property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets as follows: Research and development equipment 5 years Office and computer equipment 3 years Autos 5 years Furniture and fixtures 7 years Property and equipment, net consist of the following (in thousands): As of December 31, 2023 2022 Research and development equipment $ 1,763 $ 1,558 Office and computer equipment 808 800 Autos 54 54 Furniture and fixtures 41 41 Leasehold improvements 141 119 Total in service 2,807 2,572 Accumulated depreciation and amortization (2,419) (2,283) Total in service, net 388 289 Construction in progress — 5 Property and equipment, net $ 388 $ 294

BALANCE SHEET COMPONENTS (Table

BALANCE SHEET COMPONENTS (Tables)	12 Months Ended
	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of accounts receivable, net and activity in allowance for uncollectible accounts	Accounts receivable, net consist of the following (in thousands): As of December 31, 2023 2022 Accounts receivable $ 99 $ 119 Allowance for uncollectible accounts (4) (6) Accounts receivable, net $ 95 $ 113 The following is the activity in the allowance for uncollectible accounts (in thousands): Years Ended December 31, 2023 2022 Balance as of beginning of year $ 6 $ — Increase in provision 2 8 Amounts written off, less recoveries (4) (2) Balance as of end of year $ 4 $ 6
Schedule of inventory, net and activity in reserve for obsolescence	Inventory, net consist of the following (in thousands): As of December 31, 2023 2022 Raw materials $ 747 $ 772 Finished goods 53 99 Total inventory 800 871 Reserve for obsolescence (5) (18) Inventory, net $ 795 $ 853 The following is the activity in the reserve for obsolescence (in thousands): Years Ended December 31, 2023 2022 Balance as of beginning of year $ 18 $ 29 Increase in reserve — — Amounts relieved (13) (11) Balance as of end of year $ 5 $ 18
Schedule of prepaid expenses	Prepaid expenses consist of the following (in thousands): As of December 31, 2023 2022 Software licenses $ 152 $ 157 Prepaid inventory 111 — Insurance 64 61 Professional services 30 41 Patents 14 39 Marketing programs and conferences 1 74 Other 16 6 Total prepaid expenses $ 388 $ 378
Schedule of property and equipment, net	Depreciation on property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets as follows: Research and development equipment 5 years Office and computer equipment 3 years Autos 5 years Furniture and fixtures 7 years Property and equipment, net consist of the following (in thousands): As of December 31, 2023 2022 Research and development equipment $ 1,763 $ 1,558 Office and computer equipment 808 800 Autos 54 54 Furniture and fixtures 41 41 Leasehold improvements 141 119 Total in service 2,807 2,572 Accumulated depreciation and amortization (2,419) (2,283) Total in service, net 388 289 Construction in progress — 5 Property and equipment, net $ 388 $ 294
Schedule of accrued expenses	Accrued expenses consist of the following (in thousands): As of December 31, 2023 2022 Compensation, severance and related benefits $ 232 $ 497 Legal services 121 36 Product warranty 15 18 Personal property and franchise tax — 6 Other — 3 Total accrued expenses $ 368 $ 560
Schedule of maturities of notes payable	As of December 31, 2023, future principal payments were as follows (in thousands): 2024 $ 33 2025 36 2026 39 2027 43 2028 38 Total principal payments 189 Less: current portion of notes payable (33) Notes payable, less current portion $ 156

LEASES (Tables)

LEASES (Tables)	12 Months Ended
	Dec. 31, 2023
Leases [Abstract]
Schedule of components of lease cost	The components of lease cost are as follows (in thousands): Years Ended December 31, 2023 2022 Operating lease cost $ 231 $ 222 Finance lease cost: Amortization of ROU asset — 35 Interest on lease liability — 1 Total finance lease cost $ — $ 36
Schedule of maturities of operating lease liabilities	As of December 31, 2023, maturities of operating lease liabilities are follows (in thousands): Years Ending December 31: 2024 $ 225 Total operating lease payments 225 Less imputed interest (8) Total operating lease liabilities $ 217

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	12 Months Ended
	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of fair value of options granted	Fair value of options granted is determined using the Black-Scholes option-pricing model with the following weighted average assumptions: 2023 2022 Risk-free interest rate 5.3 % 3.7 % Expected dividend yield — % — % Expected volatility 128 % 90.5 % Expected term (in years) 5.0 3.3
Schedule of stock option activity	The stock option activity consists of the following: Number of Weighted Weighted Aggregate Intrinsic Value (1) Outstanding as of December 31, 2021 4,533 $ 2,071.20 3.9 $ — Granted 20,163 69.48 5.0 — Exercised — — — — Forfeited (1,278) — — — Expired (16) — — — Outstanding as of December 31, 2022 23,402 204.00 3.9 — Granted 16,616 15.00 5.0 — Exercised — — — — Forfeited (3,282) — — — Expired (28) — — — Outstanding as of December 31, 2023 36,708 119.70 4.0 — Exercisable as of December 31, 2023 20,634 (2) 154.31 3.8 — (1) Calculated based on the difference between the estimated fair value of our stock and the exercise price of the underlying option. The estimated stock values used in the calculation was $15.00 and $71.52 per share for the years ended December 31, 2023 and 2022, respectively. (2) Includes options related to 8,249 shares that are inducement awards and not granted under the 2018 Plan.
Schedule of restricted stock unit activity	The restricted stock unit activity consists of the following: Number of Weighted Average Outstanding as of December 31, 2021 2 $ 432.00 Granted 1,587 34.44 Vested (23) 212.04 Forfeited — — Outstanding as of December 31, 2022 1,566 32.52 Granted — — Vested (1,566) 32.52 Forfeited — — Outstanding as of December 31, 2023 — —
Schedule of stock-based compensation expense	The stock-based compensation expense was recorded as following (in thousands): Years Ended December 31, 2023 2022 Research and development $ 17 $ 3 General and administrative 538 (1) 708 Total stock-based compensation expense $ 555 $ 711 (1) Includes $100,000 related to stock issued in exchange for marketing services.

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Schedule of reconciliation of income tax	The significant differences between the U.S. Federal statutory rate and our effective rate for financial reporting purposes are as follows: Years Ended December 31, 2023 2022 Federal statutory tax rate (21.0) % (21.0) % State taxed, net of federal tax benefit (3.8) (3.7) Change in valuation allowance 23.5 14.3 Return-to-provision and other 0.1 7.9 Stock-based compensation 1.2 2.5 Effective tax rate — % — %
Schedule of deferred tax assets and liabilities	Deferred income tax assets and liabilities consist of the following (in thousands): As of December 31, 2023 2022 Deferred income tax assets: Federal and state net operating loss carryovers $ 22,167 $ 20,498 Capitalized research costs 608 432 Stock-based compensation 260 253 Compensation accruals and other 59 92 Operating leases related to ROU assets 54 89 Deferred revenue 4 11 Depreciation 11 8 Other 2 1 Total deferred income tax assets 23,165 21,384 Valuation allowance for deferred income tax assets (23,113) (21,298) Deferred income tax assets, net of valuation allowance 52 86 Deferred income tax liabilities: ROU assets (52) (86) Total deferred income tax liabilities (52) (86) Deferred income tax assets, net $ — $ —

COMMON STOCK WARRANTS (Tables)

COMMON STOCK WARRANTS (Tables)	12 Months Ended
	Dec. 31, 2023
Equity [Abstract]
Schedule of common stock warrant activity	The following is the activity for common stock warrants: Issue Date Warrant Type Term Exercise Balance Issued Exercised Expired Balance Issued Exercised Expired Balance November 2017 Common Stock Offering November 2022 $ 327.84 507 — — (507) — — — — — June 2018 Reissue December 2023 8,736.00 236 — — — 236 — — (236) — August 2018 Rights Offering July 2023 5,520.00 843 — — — 843 — — (843) — August 2018 Dealer Manager August 2023 8,280.00 55 — — — 55 — — (55) — July 2019 Dealer Manager July 2024 8,100.00 37 — — — 37 — — — 37 January 2020 Registered Direct Offering July 2025 2,160.00 765 — — — 765 — — — 765 January 2020 Dealer Manager July 2025 2,400.00 57 — — — 57 — — — 57 March 2020 Dealer Manager March 2025 901.51 57 — — — 57 — — — 57 April 2020 Dealer Manager April 2025 952.80 493 — — — 493 — — — 493 April 2020 Registered Direct Offering April 2025 732.00 209 — — — 209 — — — 209 October 2020 Private Inducement November 2027 37.98 4,166 — — — 4,166 — (4,166) — — October 2020 Dealer Manager April 2026 517.44 356 — — — 356 — — — 356 February 2021 Private Placement Agreement August 2026 531.84 6,867 — — — 6,867 — — (1,372) 5,495 February 2021 Private Placement Agreement November 2027 37.98 2,285 — — — 2,285 — (2,285) — — February 2021 Dealer Manager August 2026 683.54 1,374 — — — 1,374 — — — 1,374 March 2021 Dealer Manager March 2026 600.00 619 — — — 619 — — — 619 November 2022 Pre-Funded Warrants February 2023 42.00 — 113,416 (10,916) — 102,500 — (102,500) — — November 2022 Series A November 2027 37.98 — 119,047 — — 119,047 — (119,047) — — November 2022 Series B December 2023 37.98 — 119,047 — — 119,047 — (119,047) — — November 2022 Dealer Manager November 2027 52.50 — 8,931 — — 8,931 — — — 8,931 April 2023 Series C October 2028 19.44 — — — — — 71,430 — — 71,430 April 2023 Dealer Manager April 2028 26.25 — — — — — 5,359 — — 5,359 August 2023 Private Inducement September 2024 8.64 — — — — — 238,096 — — 238,096 August 2023 Private Inducement August 2028 8.64 — — — — — 251,001 — — 251,001 August 2023 Dealer Manager August 2028 10.80 — — — — — 12,229 — — 12,229 November 2023 Pre-Funded Warrants December 2023 1.30 — — — — — 3,395,848 (3,395,848) — — November 2023 Series D November 2028 1.30 — — — — — 3,846,154 (30,000) — 3,816,154 November 2023 Series E May 2025 1.30 — — — — — 3,846,154 (771,544) — 3,074,610 November 2023 Dealer Manager November 2028 1.63 — — — — — 288,462 — — 288,462 18,926 360,441 (10,916) (507) 367,944 11,954,733 (4,544,437) (2,506) 7,775,734 As of December 31, 2023, we had 7,775,734 shares of common stock issuable upon exercise of outstanding common stock warrants, at a weighted-average exercise price of $2.95 per share and expiring as follows: Weighted Average Exercise Price Shares Years Ending December 31: 2024 $ 9.90 238,133 2025 2.10 3,076,191 2026 563.14 7,844 2027 52.50 8,931 2028 2.08 4,444,635 2.95 7,775,734
Schedule of common stock warrant expiration information	The following is the activity for common stock warrants: Issue Date Warrant Type Term Exercise Balance Issued Exercised Expired Balance Issued Exercised Expired Balance November 2017 Common Stock Offering November 2022 $ 327.84 507 — — (507) — — — — — June 2018 Reissue December 2023 8,736.00 236 — — — 236 — — (236) — August 2018 Rights Offering July 2023 5,520.00 843 — — — 843 — — (843) — August 2018 Dealer Manager August 2023 8,280.00 55 — — — 55 — — (55) — July 2019 Dealer Manager July 2024 8,100.00 37 — — — 37 — — — 37 January 2020 Registered Direct Offering July 2025 2,160.00 765 — — — 765 — — — 765 January 2020 Dealer Manager July 2025 2,400.00 57 — — — 57 — — — 57 March 2020 Dealer Manager March 2025 901.51 57 — — — 57 — — — 57 April 2020 Dealer Manager April 2025 952.80 493 — — — 493 — — — 493 April 2020 Registered Direct Offering April 2025 732.00 209 — — — 209 — — — 209 October 2020 Private Inducement November 2027 37.98 4,166 — — — 4,166 — (4,166) — — October 2020 Dealer Manager April 2026 517.44 356 — — — 356 — — — 356 February 2021 Private Placement Agreement August 2026 531.84 6,867 — — — 6,867 — — (1,372) 5,495 February 2021 Private Placement Agreement November 2027 37.98 2,285 — — — 2,285 — (2,285) — — February 2021 Dealer Manager August 2026 683.54 1,374 — — — 1,374 — — — 1,374 March 2021 Dealer Manager March 2026 600.00 619 — — — 619 — — — 619 November 2022 Pre-Funded Warrants February 2023 42.00 — 113,416 (10,916) — 102,500 — (102,500) — — November 2022 Series A November 2027 37.98 — 119,047 — — 119,047 — (119,047) — — November 2022 Series B December 2023 37.98 — 119,047 — — 119,047 — (119,047) — — November 2022 Dealer Manager November 2027 52.50 — 8,931 — — 8,931 — — — 8,931 April 2023 Series C October 2028 19.44 — — — — — 71,430 — — 71,430 April 2023 Dealer Manager April 2028 26.25 — — — — — 5,359 — — 5,359 August 2023 Private Inducement September 2024 8.64 — — — — — 238,096 — — 238,096 August 2023 Private Inducement August 2028 8.64 — — — — — 251,001 — — 251,001 August 2023 Dealer Manager August 2028 10.80 — — — — — 12,229 — — 12,229 November 2023 Pre-Funded Warrants December 2023 1.30 — — — — — 3,395,848 (3,395,848) — — November 2023 Series D November 2028 1.30 — — — — — 3,846,154 (30,000) — 3,816,154 November 2023 Series E May 2025 1.30 — — — — — 3,846,154 (771,544) — 3,074,610 November 2023 Dealer Manager November 2028 1.63 — — — — — 288,462 — — 288,462 18,926 360,441 (10,916) (507) 367,944 11,954,733 (4,544,437) (2,506) 7,775,734 As of December 31, 2023, we had 7,775,734 shares of common stock issuable upon exercise of outstanding common stock warrants, at a weighted-average exercise price of $2.95 per share and expiring as follows: Weighted Average Exercise Price Shares Years Ending December 31: 2024 $ 9.90 238,133 2025 2.10 3,076,191 2026 563.14 7,844 2027 52.50 8,931 2028 2.08 4,444,635 2.95 7,775,734

LOSS PER SHARE (Tables)

LOSS PER SHARE (Tables)	12 Months Ended
	Dec. 31, 2023
Earnings Per Share [Abstract]
Schedule of outstanding potentially dilutive securities	The following shares were excluded from the calculation of diluted loss per share: December 31, 2023 2022 Common stock warrants 6,755,010 172,473 Restricted stock units — 1,567 Common stock options — 10,052 Total 6,755,010 184,092

BASIS OF PRESENTATION (Details)

BASIS OF PRESENTATION (Details) $ in Thousands		2 Months Ended	12 Months Ended
	Nov. 16, 2023	Dec. 31, 2023 USD ($) state territory	Dec. 31, 2023 USD ($) state territory	Dec. 31, 2022 USD ($)
Organization and Description of Business [Line Items]
Number of states registration received		50	50
Number of states approved removal of Restricted Use designation		49	49
Number of major U.S. territories registration received | territory		5	5
Stock split ratio, common stock	0.0833		0.0833	0.05
Accumulated deficit | $		$ 129,913	$ 129,913	$ 122,203
Cash and cash equivalents | $		$ 5,395	$ 5,395	$ 4,775
Evolve
Organization and Description of Business [Line Items]
Number of states authorized to sell product		30

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Money market fund	$ 4,200,000	$ 4,400,000
Advertising costs	238,000	369,000
Uncertain tax positions	0	0
Uncertain tax positions, interest or penalties expensed	$ 0	$ 0

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and equipment useful lives (Details)	Dec. 31, 2023
Research and development equipment
Property, Plant and Equipment [Line Items]
Property and equipment, useful life	5 years
Office and computer equipment
Property, Plant and Equipment [Line Items]
Property and equipment, useful life	3 years
Autos
Property, Plant and Equipment [Line Items]
Property and equipment, useful life	5 years
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, useful life	7 years

BALANCE SHEET COMPONENTS - Sche

BALANCE SHEET COMPONENTS - Schedule of accounts receivable, net (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accounts receivable	$ 99	$ 119
Allowance for uncollectible accounts	(4)	(6)	$ 0
Accounts receivable, net	$ 95	$ 113

BALANCE SHEET COMPONENTS - Sc_2

BALANCE SHEET COMPONENTS - Schedule of allowance for uncollectible accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Balance as of beginning of year	$ 6	$ 0
Increase in provision	2	8
Amounts written off, less recoveries	(4)	(2)
Balance as of end of year	$ 4	$ 6

BALANCE SHEET COMPONENTS - Sc_3

BALANCE SHEET COMPONENTS - Schedule of inventory, net (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials	$ 747	$ 772
Finished goods	53	99
Total inventory	800	871
Reserve for obsolescence	(5)	(18)	$ (29)
Inventory, net	$ 795	$ 853

BALANCE SHEET COMPONENTS - Sc_4

BALANCE SHEET COMPONENTS - Schedule of activity in reserve for obsolescence (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Inventory, Valuation Reserves [Roll Forward]
Balance as of beginning of year	$ 18	$ 29
Increase in reserve	0	0
Amounts relieved	(13)	(11)
Balance as of end of year	$ 5	$ 18

BALANCE SHEET COMPONENTS - Sc_5

BALANCE SHEET COMPONENTS - Schedule of prepaid expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Software licenses	$ 152	$ 157
Prepaid inventory	111	0
Insurance	64	61
Professional services	30	41
Patents	14	39
Marketing programs and conferences	1	74
Other	16	6
Prepaid expenses	$ 388	$ 378

BALANCE SHEET COMPONENTS - Sc_6

BALANCE SHEET COMPONENTS - Schedule of property and equipment, net (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Accumulated depreciation and amortization	$ (2,419)	$ (2,283)
Total property, plant and equipment, net	388	294
Depreciable Property, Plant And Equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	2,807	2,572
Total property, plant and equipment, net	388	289
Research and development equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	1,763	1,558
Office and computer equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	808	800
Autos
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	54	54
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	41	41
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	141	119
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 0	$ 5

BALANCE SHEET COMPONENTS - Narr

BALANCE SHEET COMPONENTS - Narrative (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Depreciation and amortization expense		$ 135	$ 183
Notes Payable
Debt Instrument [Line Items]
Debt, annual interest rate	9.10%	9.10%
Debt, term	5 years

BALANCE SHEET COMPONENTS - Sc_7

BALANCE SHEET COMPONENTS - Schedule of accrued expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Compensation, severance and related benefits	$ 232	$ 497
Legal services	121	36
Product warranty	15	18
Personal property and franchise tax	0	6
Other	0	3
Accrued expenses	$ 368	$ 560

BALANCE SHEET COMPONENTS - Sc_8

BALANCE SHEET COMPONENTS - Schedule of notes payable maturities (Details) - Notes Payable $ in Thousands	Dec. 31, 2023 USD ($)
Debt Instrument [Line Items]
2024	$ 33
2025	36
2026	39
2027	43
2028	38
Total principal payments	189
Less: current portion of notes payable	(33)
Notes payable, less current portion	$ 156

LEASES - Schedule of lease cost

LEASES - Schedule of lease cost (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Leases [Abstract]
Operating lease cost	$ 231	$ 222
Finance lease cost:
Amortization of ROU asset	0	35
Interest on lease liability	0	1
Total finance lease cost	$ 0	$ 36

LEASES - Schedule of maturities

LEASES - Schedule of maturities of operating leases liabilities (Details) $ in Thousands	Dec. 31, 2023 USD ($)
Leases [Abstract]
2024	$ 225
Total operating lease payments	225
Less imputed interest	(8)
Total operating lease liabilities	$ 217

STOCK-BASED COMPENSATION - Narr

STOCK-BASED COMPENSATION - Narrative (Details) - 2018 Equity Incentive Plan - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2019	Oct. 12, 2022
Stock-Based Compensation (Details) [Line Items]
Shares authorized (in shares)				70,717
Common stock available for issuance (in shares)	42,008
Options, contractual life	5 years
Unrecognized compensation cost	$ 293,000
Stock Options
Stock-Based Compensation (Details) [Line Items]
Options, term			5 years
Weighted average grant date fair value (in dollars per share)	$ 14.88	$ 41.04
Expected dividend yield	$ 0
Unrecognized compensation cost, period of recognition	13 months
Stock Options | Minimum
Stock-Based Compensation (Details) [Line Items]
Options, vesting period			2 months
Stock Options | Maximum
Stock-Based Compensation (Details) [Line Items]
Options, vesting period			36 months

STOCK-BASED COMPENSATION - Sche

STOCK-BASED COMPENSATION - Schedule of fair value of options granted (Details) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Share price (in dollars per share)	$ 15	$ 71.52
Stock Options | 2018 Equity Incentive Plan
Stock-Based Compensation (Details) [Line Items]
Risk-free interest rate	5.30%	3.70%
Expected dividend yield	0%	0%
Expected volatility	128%	90.50%
Expected term (in years)	5 years	3 years 3 months 18 days

STOCK-BASED COMPENSATION - Sc_2

STOCK-BASED COMPENSATION - Schedule of stock option activity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Number of Options
Beginning Balance (in shares)	23,402	4,533
Granted (in shares)	16,616	20,163
Exercised (in shares)	0	0
Forfeited (in shares)	(3,282)	(1,278)
Expired (in shares)	(28)	(16)
Ending Balance (in shares)	36,708	23,402	4,533
Number of Options, Exercisable (in shares)	20,634
Weighted Average Exercise Price Per Share
Beginning Balance (in dollars per share)	$ 204	$ 2,071.2
Granted (in dollars per share)	15	69.48
Exercised (in dollars per share)	0	0
Forfeited (in dollars per share)	0	0
Expired (in dollars per share)	0	0
Ending Balance (in dollars per share)	119.70	$ 204	$ 2,071.2
Weighted Average Exercise Price Per Share, Exercisable (in dollars per share)	$ 154.31
Weighted Average Remaining Contractual Term (years)
Outstanding	4 years	3 years 10 months 24 days	3 years 10 months 24 days
Granted	5 years	5 years
Exercisable	3 years 9 months 18 days
Aggregate Intrinsic Value
Beginning Balance	$ 0	$ 0
Granted	0	0
Exercised	0	0
Forfeited	0	0
Expired	0	0
Ending Balance	0	$ 0	$ 0
Exercisable	$ 0
Options, Inducement Award
Number of Options
Number of Options, Exercisable (in shares)	8,249

STOCK-BASED COMPENSATION - Sc_3

STOCK-BASED COMPENSATION - Schedule of restricted stock unit activity (Details) - Restricted Stock Units - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Number of Units
Beginning Balance (in shares)	1,566	2
Granted (in shares)	0	1,587
Vested (in shares)	(1,566)	(23)
Forfeited (in shares)	0	0
Ending Balance (in shares)	0	1,566
Weighted Average Grant Date Fair Value Per Unit
Beginning Balance (in dollars per share)	$ 32.52	$ 432
Granted (in dollars per share)	0	34.44
Vested (in dollars per share)	32.52	212.04
Forfeited (in dollars per share)	0	0
Ending Balance (in dollars per share)	$ 0	$ 32.52

STOCK-BASED COMPENSATION - Sc_4

STOCK-BASED COMPENSATION - Schedule of stock-based compensation expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Stock-Based Compensation (Details) [Line Items]
Total stock-based compensation expense	$ 555	$ 711
Issuance of common stock for services	100	4
Research and development
Stock-Based Compensation (Details) [Line Items]
Total stock-based compensation expense	17	3
General and administrative
Stock-Based Compensation (Details) [Line Items]
Total stock-based compensation expense	538	$ 708
Issuance of common stock for services	$ 100

INCOME TAXES - Narrative (Detai

INCOME TAXES - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Current income taxes	$ 0	$ 0
Deferred income taxes	0	0
Operating loss carryforwards, federal	91,200,000
Operating loss carryforwards, state	78,000,000
Net operating losses that do not expire	46,800,000
Unrecognized tax benefits	0	$ 0
Uncertain tax positions, interest or penalties accrued	$ 0

INCOME TAXES - Schedule of reco

INCOME TAXES - Schedule of reconciliation on income taxes (Details)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Federal statutory tax rate	(21.00%)	(21.00%)
State taxed, net of federal tax benefit	(3.80%)	(3.70%)
Change in valuation allowance	23.50%	14.30%
Return-to-provision and other	0.10%	7.90%
Stock-based compensation	1.20%	2.50%
Effective tax rate	0%	0%

INCOME TAXES - Schedule of defe

INCOME TAXES - Schedule of deferred tax assets and liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Deferred income tax assets:
Federal and state net operating loss carryovers	$ 22,167	$ 20,498
Capitalized research costs	608	432
Stock-based compensation	260	253
Compensation accruals and other	59	92
Operating leases related to ROU assets	54	89
Deferred revenue	4	11
Depreciation	11	8
Other	2	1
Total deferred income tax assets	23,165	21,384
Valuation allowance for deferred income tax assets	(23,113)	(21,298)
Deferred income tax assets, net of valuation allowance	52	86
Deferred income tax liabilities:
ROU assets	(52)	(86)
Total deferred income tax liabilities	(52)	(86)
Deferred income tax assets, net	$ 0	$ 0

STOCKHOLDERS_ EQUITY (Details)

STOCKHOLDERS’ EQUITY (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended				3 Months Ended	12 Months Ended
	Nov. 30, 2023	Apr. 30, 2023	Dec. 31, 2022	Nov. 30, 2022	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Stockholders’ Deficit (Details) [Line Items]
Preferred stock, shares authorized (in shares)			10,000,000			10,000,000	10,000,000
Preferred stock, par value (in dollars per share)			$ 0.001			$ 0.001	$ 0.001
Preferred stock, shares outstanding (in shares)			0			0	0
Common stock, shares authorized (in shares)			100,000,000			100,000,000	100,000,000
Common stock, par value (in dollars per share)			$ 0.001			$ 0.001	$ 0.001
Common stock sold (in shares)	450,306	71,429		5,631
Common stock sold, price per share (in dollars per share)	$ 1.30	$ 21		$ 42
Number of warrants (in shares)						7,775,734
Exercise price per share (in dollars per share)						$ 2.95
Warrants, exercised (in shares)						4,544,437	10,916
Common Stock Warrants Issued In November 2022
Stockholders’ Deficit (Details) [Line Items]
Gross proceeds, warrants exercised				$ 5,000
Placement agent fees and offering expenses				$ 770
Pre-Funded Warrants
Stockholders’ Deficit (Details) [Line Items]
Exercise price per share (in dollars per share)				$ 42		$ 42
Warrants, exercised (in shares)			10,916		102,500	102,500	10,916
Pre-Funded Warrants | Maximum
Stockholders’ Deficit (Details) [Line Items]
Number of warrants (in shares)				113,416
Series A and Series B Warrants Issued in November 2022 Common Stock Registered Direct Offering
Stockholders’ Deficit (Details) [Line Items]
Exercise price per share (in dollars per share)				$ 37.98
Series A and Series B Warrants Issued in November 2022 Common Stock Registered Direct Offering | Maximum
Stockholders’ Deficit (Details) [Line Items]
Number of warrants (in shares)				238,094
Warrants Issued in November 2022 Common Stock Registered Direct Offering | H.C. Wainwright & Co., LLC
Stockholders’ Deficit (Details) [Line Items]
Exercise price per share (in dollars per share)				$ 52.50
Warrants Issued in November 2022 Common Stock Registered Direct Offering | Maximum | H.C. Wainwright & Co., LLC
Stockholders’ Deficit (Details) [Line Items]
Number of warrants (in shares)				8,931
Series C Warrants
Stockholders’ Deficit (Details) [Line Items]
Exercise price per share (in dollars per share)		$ 19.44				$ 19.44
Gross proceeds, warrants exercised		$ 1,500
Placement agent fees and offering expenses		$ 290
Warrants, exercised (in shares)						0	0
Series C Warrants | H.C. Wainwright & Co., LLC
Stockholders’ Deficit (Details) [Line Items]
Exercise price per share (in dollars per share)		$ 26.25
Series C Warrants | Maximum
Stockholders’ Deficit (Details) [Line Items]
Number of warrants (in shares)		71,430
Series C Warrants | Maximum | H.C. Wainwright & Co., LLC
Stockholders’ Deficit (Details) [Line Items]
Number of warrants (in shares)		5,359
Pre-Funded Warrants Issued In November 2023, Series D Warrants, And Series E Warrants
Stockholders’ Deficit (Details) [Line Items]
Gross proceeds, warrants exercised	$ 5,000
Placement agent fees and offering expenses	$ 800
Pre-Funded Warrants Issued In November 2023, Series D Warrants, And Series E Warrants | H.C. Wainwright & Co., LLC
Stockholders’ Deficit (Details) [Line Items]
Exercise price per share (in dollars per share)	$ 1.630
Pre-Funded Warrants Issued In November 2023, Series D Warrants, And Series E Warrants | Maximum | H.C. Wainwright & Co., LLC
Stockholders’ Deficit (Details) [Line Items]
Number of warrants (in shares)	288,462
Pre-Funded Warrants Issued in November 2023
Stockholders’ Deficit (Details) [Line Items]
Exercise price per share (in dollars per share)	$ 1.30					$ 1.30
Warrants, exercised (in shares)						3,395,848	0
Pre-Funded Warrants Issued in November 2023 | Maximum
Stockholders’ Deficit (Details) [Line Items]
Number of warrants (in shares)	3,395,848
Series D Warrants and Series E Warrants
Stockholders’ Deficit (Details) [Line Items]
Exercise price per share (in dollars per share)	$ 1.30
Series D Warrants and Series E Warrants | Maximum
Stockholders’ Deficit (Details) [Line Items]
Number of warrants (in shares)	7,692,308

COMMON STOCK WARRANTS - Schedul

COMMON STOCK WARRANTS - Schedule of common stock warrant activity (Details) - $ / shares	1 Months Ended	3 Months Ended	12 Months Ended
	Dec. 31, 2022	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022	Nov. 30, 2023	Apr. 30, 2023	Nov. 30, 2022
Class of Warrant or Right [Line Items]
Exercise Price (in dollars per share)			$ 2.95
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)		367,944	367,944	18,926
Issued (in shares)			11,954,733	360,441
Exercised (in shares)			(4,544,437)	(10,916)
Expired (in shares)			(2,506)	(507)
Ending Balance (in shares)	367,944			367,944
Common Stock Offering
Class of Warrant or Right [Line Items]
Warrant Type			Common Stock Offering
Term Date			November 2022
Exercise Price (in dollars per share)			$ 327.84
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)		0	0	507
Issued (in shares)			0	0
Exercised (in shares)			0	0
Expired (in shares)			0	(507)
Ending Balance (in shares)	0		0	0
Reissue
Class of Warrant or Right [Line Items]
Warrant Type			Reissue
Term Date			December 2023
Exercise Price (in dollars per share)			$ 8,736
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)		236	236	236
Issued (in shares)			0	0
Exercised (in shares)			0	0
Expired (in shares)			(236)	0
Ending Balance (in shares)	236		0	236
Rights Offering
Class of Warrant or Right [Line Items]
Warrant Type			Rights Offering
Term Date			July 2023
Exercise Price (in dollars per share)			$ 5,520
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)		843	843	843
Issued (in shares)			0	0
Exercised (in shares)			0	0
Expired (in shares)			(843)	0
Ending Balance (in shares)	843		0	843
Dealer Manager
Class of Warrant or Right [Line Items]
Warrant Type			Dealer Manager
Term Date			August 2023
Exercise Price (in dollars per share)			$ 8,280
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)		55	55	55
Issued (in shares)			0	0
Exercised (in shares)			0	0
Expired (in shares)			(55)	0
Ending Balance (in shares)	55		0	55
Dealer Manager
Class of Warrant or Right [Line Items]
Warrant Type			Dealer Manager
Term Date			July 2024
Exercise Price (in dollars per share)			$ 8,100
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)		37	37	37
Issued (in shares)			0	0
Exercised (in shares)			0	0
Expired (in shares)			0	0
Ending Balance (in shares)	37		37	37
Registered Direct Offering
Class of Warrant or Right [Line Items]
Warrant Type			Registered Direct Offering
Term Date			July 2025
Exercise Price (in dollars per share)			$ 2,160
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)		765	765	765
Issued (in shares)			0	0
Exercised (in shares)			0	0
Expired (in shares)			0	0
Ending Balance (in shares)	765		765	765
Dealer Manager
Class of Warrant or Right [Line Items]
Warrant Type			Dealer Manager
Term Date			July 2025
Exercise Price (in dollars per share)			$ 2,400
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)		57	57	57
Issued (in shares)			0	0
Exercised (in shares)			0	0
Expired (in shares)			0	0
Ending Balance (in shares)	57		57	57
Dealer Manager
Class of Warrant or Right [Line Items]
Warrant Type			Dealer Manager
Term Date			March 2025
Exercise Price (in dollars per share)			$ 901.51
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)		57	57	57
Issued (in shares)			0	0
Exercised (in shares)			0	0
Expired (in shares)			0	0
Ending Balance (in shares)	57		57	57
Dealer Manager
Class of Warrant or Right [Line Items]
Warrant Type			Dealer Manager
Term Date			April 2025
Exercise Price (in dollars per share)			$ 952.80
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)		493	493	493
Issued (in shares)			0	0
Exercised (in shares)			0	0
Expired (in shares)			0	0
Ending Balance (in shares)	493		493	493
Registered Direct Offering
Class of Warrant or Right [Line Items]
Warrant Type			Registered Direct Offering
Term Date			April 2025
Exercise Price (in dollars per share)			$ 732
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)		209	209	209
Issued (in shares)			0	0
Exercised (in shares)			0	0
Expired (in shares)			0	0
Ending Balance (in shares)	209		209	209
Private Inducement
Class of Warrant or Right [Line Items]
Warrant Type			Private Inducement
Term Date			November 2027
Exercise Price (in dollars per share)			$ 37.98
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)		4,166	4,166	4,166
Issued (in shares)			0	0
Exercised (in shares)			(4,166)	0
Expired (in shares)			0	0
Ending Balance (in shares)	4,166		0	4,166
Dealer Manager
Class of Warrant or Right [Line Items]
Warrant Type			Dealer Manager
Term Date			April 2026
Exercise Price (in dollars per share)			$ 517.44
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)		356	356	356
Issued (in shares)			0	0
Exercised (in shares)			0	0
Expired (in shares)			0	0
Ending Balance (in shares)	356		356	356
Private Placement Agreement
Class of Warrant or Right [Line Items]
Warrant Type			Private Placement Agreement
Term Date			August 2026
Exercise Price (in dollars per share)			$ 531.84
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)		6,867	6,867	6,867
Issued (in shares)			0	0
Exercised (in shares)			0	0
Expired (in shares)			(1,372)	0
Ending Balance (in shares)	6,867		5,495	6,867
Private Placement Agreement
Class of Warrant or Right [Line Items]
Warrant Type			Private Placement Agreement
Term Date			November 2027
Exercise Price (in dollars per share)			$ 37.98
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)		2,285	2,285	2,285
Issued (in shares)			0	0
Exercised (in shares)			(2,285)	0
Expired (in shares)			0	0
Ending Balance (in shares)	2,285		0	2,285
Dealer Manager
Class of Warrant or Right [Line Items]
Warrant Type			Dealer Manager
Term Date			August 2026
Exercise Price (in dollars per share)			$ 683.54
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)		1,374	1,374	1,374
Issued (in shares)			0	0
Exercised (in shares)			0	0
Expired (in shares)			0	0
Ending Balance (in shares)	1,374		1,374	1,374
Dealer Manager
Class of Warrant or Right [Line Items]
Warrant Type			Dealer Manager
Term Date			March 2026
Exercise Price (in dollars per share)			$ 600
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)		619	619	619
Issued (in shares)			0	0
Exercised (in shares)			0	0
Expired (in shares)			0	0
Ending Balance (in shares)	619		619	619
Pre-Funded Warrants
Class of Warrant or Right [Line Items]
Warrant Type			Pre-Funded Warrants
Term Date			February 2023
Exercise Price (in dollars per share)			$ 42				$ 42
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)		102,500	102,500	0
Issued (in shares)			0	113,416
Exercised (in shares)	(10,916)	(102,500)	(102,500)	(10,916)
Expired (in shares)			0	0
Ending Balance (in shares)	102,500		0	102,500
Series A
Class of Warrant or Right [Line Items]
Warrant Type			Series A
Term Date			November 2027
Exercise Price (in dollars per share)			$ 37.98				37.980
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)		119,047	119,047	0
Issued (in shares)			0	119,047
Exercised (in shares)			(119,047)	0
Expired (in shares)			0	0
Ending Balance (in shares)	119,047		0	119,047
Series B
Class of Warrant or Right [Line Items]
Warrant Type			Series B
Term Date			December 2023
Exercise Price (in dollars per share)			$ 37.98				$ 37.98
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)		119,047	119,047	0
Issued (in shares)			0	119,047
Exercised (in shares)			(119,047)	0
Expired (in shares)			0	0
Ending Balance (in shares)	119,047		0	119,047
Dealer Manager
Class of Warrant or Right [Line Items]
Warrant Type			Dealer Manager
Term Date			November 2027
Exercise Price (in dollars per share)			$ 52.50
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)		8,931	8,931	0
Issued (in shares)			0	8,931
Exercised (in shares)			0	0
Expired (in shares)			0	0
Ending Balance (in shares)	8,931		8,931	8,931
Series C
Class of Warrant or Right [Line Items]
Warrant Type			Series C
Term Date			October 2028
Exercise Price (in dollars per share)			$ 19.44			$ 19.44
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)		0	0	0
Issued (in shares)			71,430	0
Exercised (in shares)			0	0
Expired (in shares)			0	0
Ending Balance (in shares)	0		71,430	0
Dealer Manager
Class of Warrant or Right [Line Items]
Warrant Type			Dealer Manager
Term Date			April 2028
Exercise Price (in dollars per share)			$ 26.25
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)		0	0	0
Issued (in shares)			5,359	0
Exercised (in shares)			0	0
Expired (in shares)			0	0
Ending Balance (in shares)	0		5,359	0
Private Inducement
Class of Warrant or Right [Line Items]
Warrant Type			Private Inducement
Term Date			September 2024
Exercise Price (in dollars per share)			$ 8.64
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)		0	0	0
Issued (in shares)			238,096	0
Exercised (in shares)			0	0
Expired (in shares)			0	0
Ending Balance (in shares)	0		238,096	0
Private Inducement
Class of Warrant or Right [Line Items]
Warrant Type			Private Inducement
Term Date			August 2028
Exercise Price (in dollars per share)			$ 8.64
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)		0	0	0
Issued (in shares)			251,001	0
Exercised (in shares)			0	0
Expired (in shares)			0	0
Ending Balance (in shares)	0		251,001	0
Dealer Manager
Class of Warrant or Right [Line Items]
Warrant Type			Dealer Manager
Term Date			August 2028
Exercise Price (in dollars per share)			$ 10.80
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)		0	0	0
Issued (in shares)			12,229	0
Exercised (in shares)			0	0
Expired (in shares)			0	0
Ending Balance (in shares)	0		12,229	0
Pre-Funded Warrants
Class of Warrant or Right [Line Items]
Warrant Type			Pre-Funded Warrants
Term Date			December 2023
Exercise Price (in dollars per share)			$ 1.30		$ 1.30
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)		0	0	0
Issued (in shares)			3,395,848	0
Exercised (in shares)			(3,395,848)	0
Expired (in shares)			0	0
Ending Balance (in shares)	0		0	0
Series D
Class of Warrant or Right [Line Items]
Warrant Type			Series D
Term Date			November 2028
Exercise Price (in dollars per share)			$ 1.30		1.30
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)		0	0	0
Issued (in shares)			3,846,154	0
Exercised (in shares)			(30,000)	0
Expired (in shares)			0	0
Ending Balance (in shares)	0		3,816,154	0
Series E
Class of Warrant or Right [Line Items]
Warrant Type			Series E
Term Date			May 2025
Exercise Price (in dollars per share)			$ 1.30		$ 1.30
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)		0	0	0
Issued (in shares)			3,846,154	0
Exercised (in shares)			(771,544)	0
Expired (in shares)			0	0
Ending Balance (in shares)	0		3,074,610	0
Dealer Manager
Class of Warrant or Right [Line Items]
Warrant Type			Dealer Manager
Term Date			November 2028
Exercise Price (in dollars per share)			$ 1.63
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)		0	0	0
Issued (in shares)			288,462	0
Exercised (in shares)			0	0
Expired (in shares)			0	0
Ending Balance (in shares)	0		288,462	0

COMMON STOCK WARRANTS - Sched_2

COMMON STOCK WARRANTS - Schedule of common stock warrant expiration information (Details)	Dec. 31, 2023 $ / shares shares
Class of Warrant or Right [Line Items]
Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 2.95
Shares (in shares) | shares	7,775,734
2024
Class of Warrant or Right [Line Items]
Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 9.90
Shares (in shares) | shares	238,133
2025
Class of Warrant or Right [Line Items]
Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 2.10
Shares (in shares) | shares	3,076,191
2026
Class of Warrant or Right [Line Items]
Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 563.14
Shares (in shares) | shares	7,844
2027
Class of Warrant or Right [Line Items]
Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 52.50
Shares (in shares) | shares	8,931
2028
Class of Warrant or Right [Line Items]
Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 2.08
Shares (in shares) | shares	4,444,635

COMMON STOCK WARRANTS - Narrati

COMMON STOCK WARRANTS - Narrative (Details) $ in Thousands	1 Months Ended
	Nov. 30, 2023 USD ($) $ / shares year month shares	Aug. 31, 2023 USD ($) $ / shares year shares	Nov. 30, 2022 USD ($) $ / shares year month shares	Dec. 31, 2023 $ / shares shares	Apr. 30, 2023 USD ($) $ / shares year shares
Class of Warrant or Right [Line Items]
Number of warrants (in shares) | shares				7,775,734
Exercise price per share (in dollars per share)				$ 2.95
Warrants Issued in November 2022 Common Stock Registered Direct Offering | H.C. Wainwright & Co., LLC
Class of Warrant or Right [Line Items]
Exercise price per share (in dollars per share)			$ 52.50
Warrants, fair value | $			$ 240
Warrants, expiration period			5 years
Warrants, exercise period following date of issuance			6 months
Warrants Issued in November 2022 Common Stock Registered Direct Offering | H.C. Wainwright & Co., LLC | Measurement Input, Share Price
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input			39
Warrants Issued in November 2022 Common Stock Registered Direct Offering | H.C. Wainwright & Co., LLC | Measurement Input, Price Volatility
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input			0.939
Warrants Issued in November 2022 Common Stock Registered Direct Offering | H.C. Wainwright & Co., LLC | Measurement Input, Expected Term
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input | year			5
Warrants Issued in November 2022 Common Stock Registered Direct Offering | H.C. Wainwright & Co., LLC | Measurement Input, Expected Dividend Rate
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input			0
Warrants Issued in November 2022 Common Stock Registered Direct Offering | H.C. Wainwright & Co., LLC | Measurement Input, Risk Free Interest Rate
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input			0.038
Warrants Issued in November 2022 Common Stock Registered Direct Offering | Maximum | H.C. Wainwright & Co., LLC
Class of Warrant or Right [Line Items]
Number of warrants (in shares) | shares			8,931
Pre-Funded Warrants Issued in November 2022 Common Stock Registered Direct Offering
Class of Warrant or Right [Line Items]
Exercise price per share (in dollars per share)			$ 42	42
Warrants, fair value | $			$ 153
Pre-Funded Warrants Issued in November 2022 Common Stock Registered Direct Offering | Measurement Input, Share Price
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input			36.36
Pre-Funded Warrants Issued in November 2022 Common Stock Registered Direct Offering | Measurement Input, Price Volatility
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input			0.939
Pre-Funded Warrants Issued in November 2022 Common Stock Registered Direct Offering | Measurement Input, Expected Term
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input | month			3
Pre-Funded Warrants Issued in November 2022 Common Stock Registered Direct Offering | Measurement Input, Expected Dividend Rate
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input			0
Pre-Funded Warrants Issued in November 2022 Common Stock Registered Direct Offering | Measurement Input, Risk Free Interest Rate
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input			0.038
Pre-Funded Warrants Issued in November 2022 Common Stock Registered Direct Offering | Maximum
Class of Warrant or Right [Line Items]
Number of warrants (in shares) | shares			113,416
Series A Warrants Issued in November 2022 Common Stock Registered Direct Offering
Class of Warrant or Right [Line Items]
Exercise price per share (in dollars per share)			$ 37.980	37.98
Warrants, fair value | $			$ 3,100
Warrants, expiration period			5 years
Series A Warrants Issued in November 2022 Common Stock Registered Direct Offering | Measurement Input, Share Price
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input			36.36
Series A Warrants Issued in November 2022 Common Stock Registered Direct Offering | Measurement Input, Price Volatility
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input			0.939
Series A Warrants Issued in November 2022 Common Stock Registered Direct Offering | Measurement Input, Expected Term
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input | year			5
Series A Warrants Issued in November 2022 Common Stock Registered Direct Offering | Measurement Input, Expected Dividend Rate
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input			0
Series A Warrants Issued in November 2022 Common Stock Registered Direct Offering | Measurement Input, Risk Free Interest Rate
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input			0.038
Series A Warrants Issued in November 2022 Common Stock Registered Direct Offering | Maximum
Class of Warrant or Right [Line Items]
Number of warrants (in shares) | shares			119,047
Series B Warrants Issued in November 2022 Common Stock Registered Direct Offering
Class of Warrant or Right [Line Items]
Exercise price per share (in dollars per share)			$ 37.98	37.98
Warrants, fair value | $			$ 1,600
Warrants, expiration period			13 months
Series B Warrants Issued in November 2022 Common Stock Registered Direct Offering | Measurement Input, Share Price
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input			36.36
Series B Warrants Issued in November 2022 Common Stock Registered Direct Offering | Measurement Input, Price Volatility
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input			0.939
Series B Warrants Issued in November 2022 Common Stock Registered Direct Offering | Measurement Input, Expected Term
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input | year			5
Series B Warrants Issued in November 2022 Common Stock Registered Direct Offering | Measurement Input, Expected Dividend Rate
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input			0
Series B Warrants Issued in November 2022 Common Stock Registered Direct Offering | Measurement Input, Risk Free Interest Rate
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input			0.038
Series B Warrants Issued in November 2022 Common Stock Registered Direct Offering | Maximum
Class of Warrant or Right [Line Items]
Number of warrants (in shares) | shares			119,047
Warrant Inducement Transaction, Modified
Class of Warrant or Right [Line Items]
Exercise price per share (in dollars per share)		$ 8.64
Additional equity costs | $		$ 657
Warrant Inducement Transaction, Modified | Measurement Input, Share Price
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input		8.18
Warrant Inducement Transaction, Modified | Measurement Input, Price Volatility
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input		0.96
Warrant Inducement Transaction, Modified | Measurement Input, Expected Term
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input | year		2.3
Warrant Inducement Transaction, Modified | Measurement Input, Expected Dividend Rate
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input		0
Warrant Inducement Transaction, Modified | Measurement Input, Risk Free Interest Rate
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input		0.050
Series C
Class of Warrant or Right [Line Items]
Exercise price per share (in dollars per share)				19.44	$ 19.44
Warrants, fair value | $					$ 1,100
Series C | Measurement Input, Share Price
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input					16.56
Series C | Measurement Input, Price Volatility
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input					1.64
Series C | Measurement Input, Expected Term
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input | year					5.5
Series C | Measurement Input, Expected Dividend Rate
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input					0
Series C | Measurement Input, Risk Free Interest Rate
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input					0.034
Series C | H.C. Wainwright & Co., LLC
Class of Warrant or Right [Line Items]
Exercise price per share (in dollars per share)					$ 26.25
Series C | Maximum
Class of Warrant or Right [Line Items]
Number of warrants (in shares) | shares					71,430
Series C | Maximum | H.C. Wainwright & Co., LLC
Class of Warrant or Right [Line Items]
Number of warrants (in shares) | shares					5,359
Dealer Warrants, April 2023
Class of Warrant or Right [Line Items]
Exercise price per share (in dollars per share)				26.25
Dealer Warrants, April 2023 | H.C. Wainwright & Co., LLC
Class of Warrant or Right [Line Items]
Exercise price per share (in dollars per share)					$ 26.25
Warrants, fair value | $					$ 82
Dealer Warrants, April 2023 | H.C. Wainwright & Co., LLC | Measurement Input, Share Price
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input					16.56
Dealer Warrants, April 2023 | H.C. Wainwright & Co., LLC | Measurement Input, Price Volatility
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input					1.65
Dealer Warrants, April 2023 | H.C. Wainwright & Co., LLC | Measurement Input, Expected Term
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input | year					5
Dealer Warrants, April 2023 | H.C. Wainwright & Co., LLC | Measurement Input, Expected Dividend Rate
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input					0
Dealer Warrants, April 2023 | H.C. Wainwright & Co., LLC | Measurement Input, Risk Free Interest Rate
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input					0.035
Dealer Warrants, April 2023 | Maximum | H.C. Wainwright & Co., LLC
Class of Warrant or Right [Line Items]
Number of warrants (in shares) | shares					5,359
Private Warrant Inducements
Class of Warrant or Right [Line Items]
Exercise price per share (in dollars per share)		$ 8.64
Private Warrant Inducements | Maximum
Class of Warrant or Right [Line Items]
Number of warrants (in shares) | shares		489,097
Private Warrant Inducement, Expire August 2028
Class of Warrant or Right [Line Items]
Exercise price per share (in dollars per share)				8.64
Warrants, fair value | $		$ 1,500
Private Warrant Inducement, Expire August 2028 | Measurement Input, Share Price
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input		8.18
Private Warrant Inducement, Expire August 2028 | Measurement Input, Price Volatility
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input		0.98
Private Warrant Inducement, Expire August 2028 | Measurement Input, Expected Term
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input | year		5
Private Warrant Inducement, Expire August 2028 | Measurement Input, Expected Dividend Rate
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input		0
Private Warrant Inducement, Expire August 2028 | Measurement Input, Risk Free Interest Rate
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input		0.044
Private Warrant Inducement, Expire August 2028 | Maximum
Class of Warrant or Right [Line Items]
Number of warrants (in shares) | shares		251,001
Private Warrant Inducement, Expire September 2024
Class of Warrant or Right [Line Items]
Exercise price per share (in dollars per share)				8.64
Warrants, fair value | $		$ 930
Private Warrant Inducement, Expire September 2024 | Measurement Input, Share Price
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input		8.18
Private Warrant Inducement, Expire September 2024 | Measurement Input, Expected Dividend Rate
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input		0
Private Warrant Inducement, Expire September 2024 | H.C. Wainwright & Co., LLC | Measurement Input, Price Volatility
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input		1.22
Private Warrant Inducement, Expire September 2024 | H.C. Wainwright & Co., LLC | Measurement Input, Expected Term
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input | year		1.1
Private Warrant Inducement, Expire September 2024 | H.C. Wainwright & Co., LLC | Measurement Input, Risk Free Interest Rate
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input		0.044
Private Warrant Inducement, Expire September 2024 | Maximum
Class of Warrant or Right [Line Items]
Number of warrants (in shares) | shares		238,096
Dealer Warrants, August 2023
Class of Warrant or Right [Line Items]
Exercise price per share (in dollars per share)				10.80
Dealer Warrants, August 2023 | H.C. Wainwright & Co., LLC
Class of Warrant or Right [Line Items]
Exercise price per share (in dollars per share)		$ 10.80
Warrants, fair value | $		$ 72
Dealer Warrants, August 2023 | H.C. Wainwright & Co., LLC | Measurement Input, Share Price
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input		8.18
Dealer Warrants, August 2023 | H.C. Wainwright & Co., LLC | Measurement Input, Price Volatility
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input		0.98
Dealer Warrants, August 2023 | H.C. Wainwright & Co., LLC | Measurement Input, Expected Term
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input | year		5
Dealer Warrants, August 2023 | H.C. Wainwright & Co., LLC | Measurement Input, Expected Dividend Rate
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input		0
Dealer Warrants, August 2023 | H.C. Wainwright & Co., LLC | Measurement Input, Risk Free Interest Rate
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input		0.054
Dealer Warrants, August 2023 | Maximum | H.C. Wainwright & Co., LLC
Class of Warrant or Right [Line Items]
Number of warrants (in shares) | shares		12,229
Pre-Funded Warrants Issued in November 2023
Class of Warrant or Right [Line Items]
Exercise price per share (in dollars per share)	$ 1.30			1.30
Warrants, fair value | $	$ 685
Pre-Funded Warrants Issued in November 2023 | Measurement Input, Share Price
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input	0.93
Pre-Funded Warrants Issued in November 2023 | Measurement Input, Price Volatility
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input	2.62
Pre-Funded Warrants Issued in November 2023 | Measurement Input, Expected Term
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input | month	1
Pre-Funded Warrants Issued in November 2023 | Measurement Input, Expected Dividend Rate
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input	0
Pre-Funded Warrants Issued in November 2023 | Measurement Input, Risk Free Interest Rate
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input	0.055
Pre-Funded Warrants Issued in November 2023 | Maximum
Class of Warrant or Right [Line Items]
Number of warrants (in shares) | shares	3,395,848
Series D
Class of Warrant or Right [Line Items]
Exercise price per share (in dollars per share)	$ 1.30			1.30
Warrants, fair value | $	$ 2,600
Series D | Measurement Input, Share Price
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input	0.93
Series D | Measurement Input, Price Volatility
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input	1.03
Series D | Measurement Input, Expected Term
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input | year	5
Series D | Measurement Input, Expected Dividend Rate
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input	0
Series D | Measurement Input, Risk Free Interest Rate
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input	0.042
Series D | Maximum
Class of Warrant or Right [Line Items]
Number of warrants (in shares) | shares	3,846,154
Series E
Class of Warrant or Right [Line Items]
Exercise price per share (in dollars per share)	$ 1.30			1.30
Warrants, fair value | $	$ 1,800
Series E | Measurement Input, Share Price
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input	0.93
Series E | Measurement Input, Price Volatility
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input	1.28
Series E | Measurement Input, Expected Term
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input | year	1.5
Series E | Measurement Input, Expected Dividend Rate
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input	0
Series E | Measurement Input, Risk Free Interest Rate
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input	0.046
Series E | Maximum
Class of Warrant or Right [Line Items]
Number of warrants (in shares) | shares	3,846,154
Dealer Warrants, November 2023
Class of Warrant or Right [Line Items]
Exercise price per share (in dollars per share)				$ 1.63
Dealer Warrants, November 2023 | H.C. Wainwright & Co., LLC
Class of Warrant or Right [Line Items]
Exercise price per share (in dollars per share)	$ 1.63
Warrants, fair value | $	$ 189
Warrants, expiration period	5 years
Warrants, exercise period following date of issuance	6 months
Dealer Warrants, November 2023 | H.C. Wainwright & Co., LLC | Measurement Input, Share Price
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input	0.93
Dealer Warrants, November 2023 | H.C. Wainwright & Co., LLC | Measurement Input, Price Volatility
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input	1.03
Dealer Warrants, November 2023 | H.C. Wainwright & Co., LLC | Measurement Input, Expected Term
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input | year	5
Dealer Warrants, November 2023 | H.C. Wainwright & Co., LLC | Measurement Input, Expected Dividend Rate
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input	0
Dealer Warrants, November 2023 | H.C. Wainwright & Co., LLC | Measurement Input, Risk Free Interest Rate
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input	0.042
Dealer Warrants, November 2023 | Maximum | H.C. Wainwright & Co., LLC
Class of Warrant or Right [Line Items]
Number of warrants (in shares) | shares	288,462

LOSS PER SHARE -Schedule of out

LOSS PER SHARE -Schedule of outstanding potentially dilutive securities (Details) - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total (in shares)	6,755,010	184,092
Common stock warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total (in shares)	6,755,010	172,473
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total (in shares)	0	1,567
Common stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total (in shares)	0	10,052

CONTINGENCIES (Details)

CONTINGENCIES (Details) $ in Thousands	1 Months Ended
	Nov. 30, 2023 USD ($)
Superior Court of The State of California, Kennan E. Kaedar Litigation | Settled Litigation
Loss Contingencies [Line Items]
Damages paid	$ 185

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Affiliated Entity | Kito Impact Foundation
Related Party Transaction [Line Items]
Payments for related party transaction	$ 4,200	$ 50,400

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) - USD ($) $ in Thousands	2 Months Ended	12 Months Ended
	Feb. 21, 2024	Dec. 31, 2023	Dec. 31, 2022
Subsequent Event | Warrants Issued, 2024, Common Stock
Subsequent Event [Line Items]
Gross proceeds, warrants exercised	$ 6
Common Stock
Subsequent Event [Line Items]
Stock issued, warrants exercised (in shares)		4,544,437	10,916
Common Stock | Subsequent Event | Warrants Issued, 2024, Common Stock
Subsequent Event [Line Items]
Stock issued, warrants exercised (in shares)	4,608